CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | hepatic steatosis inducing agent |
|
Accession: | CHEBI:83612
|
browse the term
|
Definition: | Any hepatotoxic agent capable of inducing liver steatosis or fatty liver disease. |
Synonyms: | related_synonym: | hepatic steatosis inducing agents; hepatic steatosis inducing drug; hepatic steatosis inducing drugs |
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of ABCB1A mRNA |
CTD |
PMID:8707270 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
increases expression |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of ABCB4 mRNA |
CTD |
PMID:8707270 |
|
NCBI chr 4:22,133,984...22,192,687
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Acads |
acyl-CoA dehydrogenase short chain |
decreases expression |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in decreased expression of ACADS mRNA |
CTD |
PMID:20512997 |
|
NCBI chr12:47,254,503...47,263,747
Ensembl chr12:47,254,484...47,263,747
|
|
G |
Afp |
alpha-fetoprotein |
increases expression multiple interactions |
ISO |
Dicarbethoxydihydrocollidine results in increased expression of AFP mRNA S-Adenosylmethionine inhibits the reaction [Dicarbethoxydihydrocollidine results in increased expression of AFP mRNA] |
CTD |
PMID:18098314 |
|
NCBI chr14:19,141,755...19,159,919
Ensembl chr14:19,141,755...19,159,923
|
|
G |
Alb |
albumin |
increases expression |
ISO |
Dicarbethoxydihydrocollidine results in increased expression of ALB protein |
CTD |
PMID:17585168 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
increases expression multiple interactions |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of CD44 mRNA SULT2B1 protein promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of CD44 mRNA] |
CTD |
PMID:27052460 |
|
NCBI chr 3:92,695,083...92,783,820
Ensembl chr 3:92,696,313...92,783,658
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
decreases expression |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in decreased expression of CPT2 mRNA |
CTD |
PMID:20512997 |
|
NCBI chr 5:127,505,646...127,523,016
Ensembl chr 5:127,505,614...127,523,089
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
[NFE2L2 gene mutant form results in increased susceptibility to 3,5-diethoxycarbonyl-1,4-dihydrocollidine] which results in increased expression of CSF2 protein |
CTD |
PMID:30825315 |
|
NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions decreases expression decreases response to substance |
ISO |
CTNNB1 mutant form inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine affects the localization of FOXO3 protein]; CTNNB1 mutant form inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of SGK1 protein] 3,5-diethoxycarbonyl-1,4-dihydrocollidine results in decreased expression of CTNNB1 protein CTNNB1 protein results in decreased susceptibility to 3,5-diethoxycarbonyl-1,4-dihydrocollidine |
CTD |
PMID:23620592 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
increases expression |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of CYP2B10 mRNA |
CTD |
PMID:21826054 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
increases expression |
ISO |
Dicarbethoxydihydrocollidine results in increased expression of DNMT1 mRNA |
CTD |
PMID:18098314 |
|
NCBI chr 8:21,922,515...21,968,495
Ensembl chr 8:21,922,515...21,968,495
|
|
G |
Dnmt3a |
DNA methyltransferase 3 alpha |
increases expression multiple interactions |
ISO |
Dicarbethoxydihydrocollidine results in increased expression of DNMT3A mRNA S-Adenosylmethionine inhibits the reaction [Dicarbethoxydihydrocollidine results in increased expression of DNMT3A mRNA] |
CTD |
PMID:18098314 |
|
NCBI chr 6:28,205,375...28,346,052
Ensembl chr 6:28,235,695...28,340,577
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
increases expression |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of EEF2 mRNA |
CTD |
PMID:20512997 |
|
NCBI chr 7:11,401,501...11,406,771
Ensembl chr 7:11,401,501...11,406,771
|
|
G |
Epcam |
epithelial cell adhesion molecule |
increases expression multiple interactions |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of EPCAM mRNA; 3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of EPCAM protein GW 3965 inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of EPCAM protein]; SULT2B1 protein promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of EPCAM protein] |
CTD |
PMID:21826054 PMID:27052460 |
|
NCBI chr 6:11,282,194...11,308,870
Ensembl chr 6:11,281,964...11,298,216
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
decreases expression |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in decreased expression of FABP3 mRNA |
CTD |
PMID:20512997 |
|
NCBI chr 5:148,528,854...148,535,597
Ensembl chr 5:148,528,725...148,535,565
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions affects localization |
ISO |
CTNNB1 mutant form inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine affects the localization of FOXO3 protein] |
CTD |
PMID:23620592 |
|
NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases expression multiple interactions |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of GJA1 mRNA SULT2B1 protein promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of GJA1 mRNA] |
CTD |
PMID:27052460 |
|
NCBI chr20:37,876,650...37,889,097
Ensembl chr20:37,876,650...37,889,089
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased phosphorylation of and results in decreased activity of GSK3B protein |
CTD |
PMID:20512997 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
increases expression multiple interactions |
ISO |
Dicarbethoxydihydrocollidine results in increased expression of GSTM2 mRNA S-Adenosylmethionine inhibits the reaction [Dicarbethoxydihydrocollidine results in increased expression of GSTM2 mRNA] |
CTD |
PMID:18098314 |
|
NCBI chr 2:210,778,041...210,782,807
Ensembl chr 2:210,720,704...210,782,856
|
|
G |
Hdac7 |
histone deacetylase 7 |
increases expression |
ISO |
Dicarbethoxydihydrocollidine results in increased expression of HDAC7 mRNA |
CTD |
PMID:18098314 |
|
NCBI chr 7:139,280,396...139,319,108
Ensembl chr 7:139,281,187...139,318,455
|
|
G |
Hdac9 |
histone deacetylase 9 |
increases expression multiple interactions |
ISO |
Dicarbethoxydihydrocollidine results in increased expression of HDAC9 mRNA S-Adenosylmethionine inhibits the reaction [Dicarbethoxydihydrocollidine results in increased expression of HDAC9 mRNA] |
CTD |
PMID:18098314 |
|
NCBI chr 6:53,487,367...54,358,694
Ensembl chr 6:53,488,883...54,059,119
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[NFE2L2 gene mutant form results in increased susceptibility to 3,5-diethoxycarbonyl-1,4-dihydrocollidine] which results in increased expression of IFNG protein |
CTD |
PMID:30825315 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
[NFE2L2 gene mutant form results in increased susceptibility to 3,5-diethoxycarbonyl-1,4-dihydrocollidine] which results in increased expression of IL12A protein |
CTD |
PMID:30825315 |
|
NCBI chr 2:165,076,945...165,083,996
Ensembl chr 2:165,076,607...165,084,318
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
[NFE2L2 gene mutant form results in increased susceptibility to 3,5-diethoxycarbonyl-1,4-dihydrocollidine] which results in increased expression of IL12B protein |
CTD |
PMID:30825315 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il17a |
interleukin 17A |
multiple interactions increases expression |
ISO |
NFE2L2 gene mutant form promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of IL17A protein] |
CTD |
PMID:30825315 |
|
NCBI chr 9:26,841,299...26,844,786
Ensembl chr 9:26,841,299...26,844,786
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
ISO |
[NFE2L2 gene mutant form results in increased susceptibility to 3,5-diethoxycarbonyl-1,4-dihydrocollidine] which results in increased expression of IL1B protein; NFE2L2 gene mutant form promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of IL1B mRNA] |
CTD |
PMID:30825315 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
multiple interactions increases expression |
ISO |
NFE2L2 gene mutant form promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of IL1RN mRNA] |
CTD |
PMID:30825315 |
|
NCBI chr 3:1,449,778...1,468,624
Ensembl chr 3:1,452,644...1,468,614
|
|
G |
Il3 |
interleukin 3 |
multiple interactions |
ISO |
[NFE2L2 gene mutant form results in increased susceptibility to 3,5-diethoxycarbonyl-1,4-dihydrocollidine] which results in increased expression of IL3 protein |
CTD |
PMID:30825315 |
|
NCBI chr10:39,620,535...39,622,973
Ensembl chr10:39,620,563...39,622,973
|
|
G |
Il5 |
interleukin 5 |
multiple interactions |
ISO |
[NFE2L2 gene mutant form results in increased susceptibility to 3,5-diethoxycarbonyl-1,4-dihydrocollidine] which results in increased expression of IL5 protein |
CTD |
PMID:30825315 |
|
NCBI chr10:39,066,716...39,069,587
Ensembl chr10:39,066,716...39,069,587
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of IL6 protein SULT2B1 protein promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of IL6 protein] |
CTD |
PMID:27052460 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Il6st |
interleukin 6 cytokine family signal transducer |
increases expression multiple interactions |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of IL6ST mRNA; 3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of IL6ST protein SULT2B1 protein promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of IL6ST mRNA]; SULT2B1 protein promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of IL6ST protein] |
CTD |
PMID:27052460 |
|
NCBI chr 2:44,279,199...44,319,427
Ensembl chr 2:44,289,393...44,314,944
|
|
G |
Kat2b |
lysine acetyltransferase 2B |
decreases expression |
ISO |
Dicarbethoxydihydrocollidine results in decreased expression of KAT2B mRNA |
CTD |
PMID:18098314 |
|
NCBI chr 9:4,440,982...4,492,949
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
affects response to substance decreases response to substance multiple interactions |
ISO |
KEAP1 gene affects the susceptibility to 3,5-diethoxycarbonyl-1,4-dihydrocollidine KEAP1 gene mutant form results in decreased susceptibility to 3,5-diethoxycarbonyl-1,4-dihydrocollidine KEAP1 gene mutant form promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of KRT19 mRNA] |
CTD |
PMID:30215777 PMID:30825315 |
|
NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
multiple interactions increases expression |
ISO |
SULT2B1 protein promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of KIT mRNA] |
CTD |
PMID:27052460 |
|
NCBI chr14:35,072,131...35,149,638
Ensembl chr14:35,072,108...35,149,610
|
|
G |
Klf6 |
Kruppel-like factor 6 |
increases expression multiple interactions |
ISO |
Dicarbethoxydihydrocollidine results in increased expression of KLF6 mRNA S-Adenosylmethionine inhibits the reaction [Dicarbethoxydihydrocollidine results in increased expression of KLF6 mRNA] |
CTD |
PMID:18098314 |
|
NCBI chr17:67,887,939...67,945,052
Ensembl chr17:67,887,939...67,945,037
|
|
G |
Krt18 |
keratin 18 |
increases expression |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of KRT18 mRNA |
CTD |
PMID:10751352 |
|
NCBI chr 7:143,629,455...143,633,131
Ensembl chr 7:143,629,455...143,633,131
|
|
G |
Krt19 |
keratin 19 |
increases expression multiple interactions |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of KRT19 mRNA; 3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of KRT19 protein; Dicarbethoxydihydrocollidine results in increased expression of KRT19 protein GW 3965 inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of KRT19 protein]; KEAP1 gene mutant form promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of KRT19 mRNA]; NFE2L2 gene mutant form promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of KRT19 mRNA]; SULT2B1 protein promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of KRT19 protein] |
CTD |
PMID:17585168 PMID:27052460 PMID:30825315 |
|
NCBI chr10:88,055,843...88,060,560
Ensembl chr10:88,055,841...88,060,561
|
|
G |
Krt8 |
keratin 8 |
increases expression decreases response to substance |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of KRT8 mRNA KRT8 protein results in decreased susceptibility to 3,5-diethoxycarbonyl-1,4-dihydrocollidine |
CTD |
PMID:10751352 |
|
NCBI chr 7:143,596,511...143,603,745
Ensembl chr 7:143,596,511...143,603,803
|
|
G |
Lep |
leptin |
decreases expression |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in decreased expression of LEP protein |
CTD |
PMID:20512997 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Mapt |
microtubule-associated protein tau |
increases expression |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of MAPT mRNA; 3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of MAPT mRNA alternative form; 3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of MAPT protein |
CTD |
PMID:10051481 |
|
NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
|
|
G |
Mat2a |
methionine adenosyltransferase 2A |
increases expression |
ISO |
Dicarbethoxydihydrocollidine results in increased expression of MAT2A mRNA |
CTD |
PMID:18098314 |
|
NCBI chr 4:100,297,478...100,303,047
Ensembl chr 4:100,296,075...100,303,080
|
|
G |
Myh7 |
myosin heavy chain 7 |
increases expression |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of MYH7 mRNA |
CTD |
PMID:20512997 |
|
NCBI chr15:33,605,769...33,657,761
Ensembl chr15:33,634,422...33,656,089
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions increases response to substance |
ISO |
[NFE2L2 gene mutant form results in increased susceptibility to 3,5-diethoxycarbonyl-1,4-dihydrocollidine] which results in increased expression of CSF2 protein; [NFE2L2 gene mutant form results in increased susceptibility to 3,5-diethoxycarbonyl-1,4-dihydrocollidine] which results in increased expression of IFNG protein; [NFE2L2 gene mutant form results in increased susceptibility to 3,5-diethoxycarbonyl-1,4-dihydrocollidine] which results in increased expression of IL12A protein; [NFE2L2 gene mutant form results in increased susceptibility to 3,5-diethoxycarbonyl-1,4-dihydrocollidine] which results in increased expression of IL12B protein; [NFE2L2 gene mutant form results in increased susceptibility to 3,5-diethoxycarbonyl-1,4-dihydrocollidine] which results in increased expression of IL1B protein; [NFE2L2 gene mutant form results in increased susceptibility to 3,5-diethoxycarbonyl-1,4-dihydrocollidine] which results in increased expression of IL3 protein; [NFE2L2 gene mutant form results in increased susceptibility to 3,5-diethoxycarbonyl-1,4-dihydrocollidine] which results in increased expression of IL5 protein; NFE2L2 gene mutant form promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of IL17A protein]; NFE2L2 gene mutant form promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of IL1B mRNA]; NFE2L2 gene mutant form promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of IL1RN mRNA]; NFE2L2 gene mutant form promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of KRT19 mRNA]; NFE2L2 gene mutant form promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of TNF mRNA] |
CTD |
PMID:30825315 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nppb |
natriuretic peptide B |
increases expression |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of NPPB mRNA |
CTD |
PMID:20512997 |
|
NCBI chr 5:164,796,176...164,797,538
Ensembl chr 5:164,796,185...164,797,531
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions affects response to substance |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased activity of and affects the localization of NR1I3 protein NR1I3 protein affects the susceptibility to 3,5-diethoxycarbonyl-1,4-dihydrocollidine |
CTD |
PMID:21826054 |
|
NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
|
|
G |
Pkm |
pyruvate kinase M1/2 |
multiple interactions increases expression |
ISO |
GW 3965 inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of PKM protein]; SULT2B1 protein promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of PKM protein] |
CTD |
PMID:27052460 |
|
NCBI chr 8:64,480,963...64,502,957
Ensembl chr 8:64,481,172...64,502,722
|
|
G |
Prom1 |
prominin 1 |
increases expression |
ISO |
Dicarbethoxydihydrocollidine results in increased expression of PROM1 protein |
CTD |
PMID:17585168 |
|
NCBI chr14:71,532,321...71,637,400
Ensembl chr14:71,533,063...71,637,417
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
increases expression multiple interactions |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of SGK1 protein CTNNB1 mutant form inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of SGK1 protein] |
CTD |
PMID:23620592 |
|
NCBI chr 1:24,185,451...24,302,309
Ensembl chr 1:24,185,435...24,302,298
|
|
G |
Sirt3 |
sirtuin 3 |
decreases expression |
ISO |
Dicarbethoxydihydrocollidine results in decreased expression of SIRT3 mRNA |
CTD |
PMID:18098314 |
|
NCBI chr 1:213,613,502...213,636,061
Ensembl chr 1:213,613,513...213,635,546
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
increases expression |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of SLC2A1 mRNA |
CTD |
PMID:20512997 |
|
NCBI chr 5:138,154,677...138,182,897
Ensembl chr 5:138,154,673...138,182,897
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
increases expression |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of SLC2A4 mRNA; 3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of SLC2A4 protein |
CTD |
PMID:20512997 |
|
NCBI chr10:56,552,921...56,558,562
Ensembl chr10:56,552,983...56,558,487
|
|
G |
Sult2b1 |
sulfotransferase family 2B member 1 |
increases expression multiple interactions |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of SULT2B1 mRNA; 3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of SULT2B1 protein SULT2B1 protein inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased abundance of 22-hydroxycholesterol]; SULT2B1 protein inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased abundance of 24,25-epoxycholesterol]; SULT2B1 protein inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased abundance of 25-hydroxycholesterol]; SULT2B1 protein promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of CD44 mRNA]; SULT2B1 protein promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of EPCAM protein]; SULT2B1 protein promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of GJA1 mRNA]; SULT2B1 protein promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of IL6 protein]; SULT2B1 protein promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of IL6ST mRNA]; SULT2B1 protein promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of IL6ST protein]; SULT2B1 protein promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of KIT mRNA]; SULT2B1 protein promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of KRT19 protein]; SULT2B1 protein promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of PKM protein]; SULT2B1 protein promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of THY1 mRNA] |
CTD |
PMID:27052460 |
|
NCBI chr 1:101,712,254...101,774,683
Ensembl chr 1:101,710,959...101,773,508
|
|
G |
Tacstd2 |
tumor-associated calcium signal transducer 2 |
increases expression |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of TACSTD2 mRNA |
CTD |
PMID:21826054 |
|
NCBI chr 4:98,341,187...98,342,887
Ensembl chr 4:98,341,188...98,342,887
|
|
G |
Thy1 |
Thy-1 cell surface antigen |
multiple interactions increases expression |
ISO |
SULT2B1 protein promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of THY1 mRNA] |
CTD |
PMID:27052460 |
|
NCBI chr 8:48,382,121...48,387,271
Ensembl chr 8:48,382,121...48,386,935
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
ISO |
NFE2L2 gene mutant form promotes the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of TNF mRNA] |
CTD |
PMID:30825315 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000 Ensembl chr20:5,189,390...5,192,000
|
|
G |
Ubd |
ubiquitin D |
increases expression multiple interactions |
ISO |
Dicarbethoxydihydrocollidine results in increased expression of UBD mRNA S-Adenosylmethionine inhibits the reaction [Dicarbethoxydihydrocollidine results in increased expression of UBD mRNA] |
CTD |
PMID:18098314 |
|
NCBI chr20:1,876,175...1,878,126
Ensembl chr20:1,876,173...1,897,814
|
|
G |
Ucp3 |
uncoupling protein 3 |
decreases expression |
ISO |
3,5-diethoxycarbonyl-1,4-dihydrocollidine results in decreased expression of UCP3 mRNA; 3,5-diethoxycarbonyl-1,4-dihydrocollidine results in decreased expression of UCP3 protein |
CTD |
PMID:20512997 |
|
NCBI chr 1:165,482,912...165,495,895
Ensembl chr 1:165,482,155...165,496,206
|
|
|
G |
Aadacl2 |
arylacetamide deacetylase-like 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of AADACL2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 2:150,344,307...150,365,033
Ensembl chr 2:150,344,307...150,365,033 Ensembl chr 2:150,344,307...150,365,033
|
|
G |
Aak1 |
AP2 associated kinase 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of AAK1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 4:118,653,851...118,806,796
Ensembl chr 4:118,655,728...118,795,774
|
|
G |
Abca12 |
ATP binding cassette subfamily A member 12 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ABCA12 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 9:78,521,477...78,693,421
Ensembl chr 9:78,522,464...78,693,028
|
|
G |
Abca5 |
ATP binding cassette subfamily A member 5 |
increases expression |
ISO |
sodium arsenate results in increased expression of ABCA5 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr10:98,573,226...98,645,028
Ensembl chr10:98,576,039...98,644,938
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
increases secretion multiple interactions decreases response to substance |
ISO |
ABCC1 protein results in increased secretion of sodium arsenate [MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to sodium arsenate; verlukast inhibits the reaction [ABCC1 protein results in decreased susceptibility to sodium arsenate] |
CTD |
PMID:10348353 PMID:10685512 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
ISO EXP |
sodium arsenate results in increased expression of ABCC2 mRNA sodium arsenate results in increased expression of ABCC2 mRNA; sodium arsenate results in increased expression of ABCC2 protein |
CTD |
PMID:11408547 PMID:12727804 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ABCC3 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
|
|
G |
Abcc9 |
ATP binding cassette subfamily C member 9 |
increases expression |
ISO |
sodium arsenate results in increased expression of ABCC9 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 4:176,806,098...176,928,540
Ensembl chr 4:176,805,431...176,922,424
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of ABCG1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr20:9,743,269...9,842,735
Ensembl chr20:9,743,269...9,840,489
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of ABCG2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Abcg4 |
ATP binding cassette subfamily G member 4 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ABCG4 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 8:48,604,915...48,626,219
Ensembl chr 8:48,606,403...48,619,592
|
|
G |
Abhd12b |
abhydrolase domain containing 12B |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ABHD12B mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 6:92,568,975...92,596,327
Ensembl chr 6:92,568,975...92,596,327
|
|
G |
Abhd5 |
abhydrolase domain containing 5, lysophosphatidic acid acyltransferase |
decreases expression |
ISO |
sodium arsenate results in decreased expression of ABHD5 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 8:130,973,222...131,001,448
Ensembl chr 8:130,973,201...131,001,458
|
|
G |
Abi3bp |
ABI family member 3 binding protein |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ABI3BP mRNA |
CTD |
PMID:32525701 |
|
NCBI chr11:46,206,932...46,422,791
Ensembl chr11:46,208,075...46,369,577
|
|
G |
Abl2 |
ABL proto-oncogene 2, non-receptor tyrosine kinase |
decreases expression multiple interactions |
ISO |
sodium arsenate results in decreased expression of ABL2 mRNA [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ABL2 mRNA |
CTD |
PMID:21795629 PMID:32525701 |
|
NCBI chr13:74,154,533...74,333,244
Ensembl chr13:74,154,835...74,333,244
|
|
G |
Ablim2 |
actin binding LIM protein family, member 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ABLIM2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr14:80,044,217...80,169,491
Ensembl chr14:80,045,078...80,169,472
|
|
G |
Acad9 |
acyl-CoA dehydrogenase family, member 9 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ACAD9 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 2:122,782,051...122,806,166
Ensembl chr 2:122,782,060...122,805,768
|
|
G |
Acadvl |
acyl-CoA dehydrogenase, very long chain |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ACADVL mRNA |
CTD |
PMID:32525701 |
|
NCBI chr10:56,619,321...56,624,468
Ensembl chr10:56,619,303...56,624,526
|
|
G |
Acap1 |
ArfGAP with coiled-coil, ankyrin repeat and PH domains 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ACAP1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr10:56,492,300...56,506,446
Ensembl chr10:56,492,300...56,506,446
|
|
G |
Acer1 |
alkaline ceramidase 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ACER1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 9:10,061,978...10,093,588
Ensembl chr 9:10,061,978...10,093,588
|
|
G |
Acer3 |
alkaline ceramidase 3 |
decreases expression multiple interactions |
ISO |
sodium arsenate results in decreased expression of ACER3 mRNA [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ACER3 mRNA |
CTD |
PMID:30953684 PMID:32525701 |
|
NCBI chr 1:163,160,987...163,263,621
Ensembl chr 1:163,160,979...163,263,606
|
|
G |
Ackr3 |
atypical chemokine receptor 3 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of ACKR3 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 9:97,355,881...97,367,455
Ensembl chr 9:97,355,924...97,367,445
|
|
G |
Ackr4 |
atypical chemokine receptor 4 |
increases expression |
ISO |
sodium arsenate results in increased expression of ACKR4 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 8:112,643,838...112,651,668
Ensembl chr 8:112,644,222...112,648,880
|
|
G |
Acp3 |
acid phosphatase 3 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ACP3 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 8:112,838,574...112,884,062
Ensembl chr 8:112,834,707...112,884,077
|
|
G |
Acp7 |
acid phosphatase 7, tartrate resistant |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ACP7 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 1:85,141,383...85,162,449
Ensembl chr 1:85,143,789...85,153,210
|
|
G |
Acsl4 |
acyl-CoA synthetase long-chain family member 4 |
increases expression |
ISO |
sodium arsenate results in increased expression of ACSL4 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr X:113,596,247...113,660,024
Ensembl chr X:113,596,239...113,659,944
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression |
ISO |
sodium arsenate results in increased expression of ACTA2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Actb |
actin, beta |
increases expression |
ISO |
sodium arsenate results in increased expression of ACTB mRNA |
CTD |
PMID:21795629 |
|
NCBI chr12:13,715,843...13,718,813
Ensembl chr12:13,715,843...13,718,841
|
|
G |
Actc1 |
actin, alpha, cardiac muscle 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of ACTC1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 3:105,507,403...105,512,939
Ensembl chr 3:105,507,403...105,512,939
|
|
G |
Actn1 |
actinin, alpha 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of ACTN1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 6:103,376,557...103,470,497
Ensembl chr 6:103,375,799...103,470,555
|
|
G |
Actr1b |
actin related protein 1B |
decreases expression |
ISO |
sodium arsenate results in decreased expression of ACTR1B mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 9:43,267,053...43,276,717
Ensembl chr 9:43,267,057...43,276,685
|
|
G |
Actr3b |
actin related protein 3B |
decreases expression |
ISO |
sodium arsenate results in decreased expression of ACTR3B mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 4:5,644,287...5,672,708
Ensembl chr 4:5,644,260...5,672,708 Ensembl chr 4:5,644,260...5,672,708
|
|
G |
Adam10 |
ADAM metallopeptidase domain 10 |
increases expression |
ISO |
sodium arsenate results in increased expression of ADAM10 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 8:77,107,355...77,237,483
Ensembl chr 8:77,107,536...77,237,483
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
increases expression |
ISO |
sodium arsenate results in increased expression of ADAM17 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 6:43,400,525...43,448,280
Ensembl chr 6:43,400,528...43,448,280
|
|
G |
Adam19 |
ADAM metallopeptidase domain 19 |
decreases expression increases expression |
ISO |
sodium arsenate results in decreased expression of ADAM19 mRNA sodium arsenate results in increased expression of ADAM19 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr10:31,146,107...31,240,582
Ensembl chr10:31,146,107...31,240,582
|
|
G |
Adam33 |
ADAM metallopeptidase domain 33 |
increases expression |
ISO |
sodium arsenate results in increased expression of ADAM33 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 3:123,595,018...123,607,549
Ensembl chr 3:123,595,560...123,607,352
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ADAMTS1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr11:25,342,119...25,350,938
Ensembl chr11:25,342,126...25,350,974
|
|
G |
Adamts9 |
ADAM metallopeptidase with thrombospondin type 1 motif, 9 |
increases expression |
ISO |
sodium arsenate results in increased expression of ADAMTS9 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 4:124,660,254...124,860,997
Ensembl chr 4:124,660,262...124,858,250
|
|
G |
Adamtsl1 |
ADAMTS-like 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of ADAMTSL1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 5:103,789,443...104,753,866
|
|
G |
Adap2 |
ArfGAP with dual PH domains 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ADAP2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr10:67,494,851...67,527,582
Ensembl chr10:67,494,984...67,526,426
|
|
G |
Adarb1 |
adenosine deaminase, RNA-specific, B1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of ADARB1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr20:11,972,352...12,101,022
Ensembl chr20:11,972,381...12,101,047
|
|
G |
Adgrl1 |
adhesion G protein-coupled receptor L1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ADGRL1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr19:25,029,037...25,069,146
Ensembl chr19:25,029,037...25,069,142
|
|
G |
Adh7 |
alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ADH7 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 2:243,500,540...243,516,865
Ensembl chr 2:243,502,073...243,516,532
|
|
G |
Adsl |
adenylosuccinate lyase |
decreases expression |
ISO |
sodium arsenate results in decreased expression of ADSL mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 7:122,157,201...122,192,328
Ensembl chr 7:122,157,201...122,192,328
|
|
G |
Afap1l1 |
actin filament associated protein 1-like 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of AFAP1L1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr18:57,052,659...57,114,589
Ensembl chr18:57,053,947...57,114,545
|
|
G |
Aff2 |
AF4/FMR2 family, member 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of AFF2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr X:153,539,951...154,051,022
Ensembl chr X:153,539,668...154,051,181
|
|
G |
Aga |
aspartylglucosaminidase |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of AGA mRNA |
CTD |
PMID:32525701 |
|
NCBI chr16:41,222,225...41,234,169
Ensembl chr16:41,222,238...41,234,095
|
|
G |
Agfg1 |
ArfGAP with FG repeats 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of AGFG1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 9:88,607,508...88,663,486
Ensembl chr 9:88,607,508...88,662,224
|
|
G |
Agl |
amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase |
increases expression |
ISO |
sodium arsenate results in increased expression of AGL mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 2:219,788,234...219,843,189
Ensembl chr 2:219,788,234...219,842,986
|
|
G |
Ago2 |
argonaute RISC catalytic component 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of AGO2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 7:114,339,607...114,377,277
Ensembl chr 7:114,339,434...114,380,613
|
|
G |
Ago3 |
argonaute RISC catalytic component 3 |
increases expression |
ISO |
sodium arsenate results in increased expression of AGO3 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 5:144,355,792...144,436,509
Ensembl chr 5:144,364,269...144,436,509
|
|
G |
Agr2 |
anterior gradient 2, protein disulphide isomerase family member |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of AGR2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 6:55,465,782...55,487,087
Ensembl chr 6:55,465,782...55,487,714
|
|
G |
Akap10 |
A-kinase anchoring protein 10 |
increases expression |
ISO |
sodium arsenate results in increased expression of AKAP10 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr10:48,150,902...48,210,074
Ensembl chr10:48,150,902...48,210,074
|
|
G |
Akap6 |
A-kinase anchoring protein 6 |
increases expression |
ISO |
sodium arsenate results in increased expression of AKAP6 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 6:73,553,111...73,991,992
Ensembl chr 6:73,553,210...73,990,534
|
|
G |
Aknad1 |
AKNA domain containing 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of AKNAD1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 2:211,541,800...211,585,332
Ensembl chr 2:211,546,560...211,585,332
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B |
increases expression |
ISO |
sodium arsenate results in increased expression of AKR1B1 mRNA |
CTD |
PMID:12727804 |
|
NCBI chr 4:61,706,866...61,720,959
Ensembl chr 4:61,706,864...61,720,956
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of AKR1B10 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 4:61,813,265...61,830,371
Ensembl chr 4:61,771,970...61,828,657
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of AKR1C4 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr17:69,441,253...69,460,334
Ensembl chr17:69,441,223...69,460,321
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of AKR1C2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr17:69,388,337...69,435,160
Ensembl chr17:69,388,335...69,404,341
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of AKR1C3 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of AKT1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Akt3 |
AKT serine/threonine kinase 3 |
increases expression |
ISO |
sodium arsenate results in increased expression of AKT3 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr13:95,076,308...95,348,913
Ensembl chr13:95,081,390...95,348,913
|
|
G |
Aktip |
AKT interacting protein |
increases expression |
ISO |
sodium arsenate results in increased expression of AKTIP mRNA |
CTD |
PMID:30953684 |
|
NCBI chr19:17,290,048...17,300,054
Ensembl chr19:17,290,178...17,300,050
|
|
G |
Alas2 |
5'-aminolevulinate synthase 2 |
decreases expression increases expression |
ISO |
sodium arsenate results in decreased expression of ALAS2 mRNA sodium arsenate results in increased expression of ALAS2 mRNA |
CTD |
PMID:21795629 PMID:30953684 |
|
NCBI chr X:23,167,576...23,187,356
Ensembl chr X:23,167,696...23,187,341
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
[imidacloprid co-treated with sodium arsenate] results in decreased expression of ALB protein |
CTD |
PMID:30033815 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Alcam |
activated leukocyte cell adhesion molecule |
increases expression |
ISO |
sodium arsenate results in increased expression of ALCAM mRNA |
CTD |
PMID:21795629 |
|
NCBI chr11:50,780,735...50,985,083
Ensembl chr11:50,781,127...50,985,083
|
|
G |
Aldh18a1 |
aldehyde dehydrogenase 18 family, member A1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of ALDH18A1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 1:259,641,673...259,674,521
Ensembl chr 1:259,641,676...259,674,425 Ensembl chr 1:259,641,676...259,674,425
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of ALDH1A2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 8:77,640,234...77,719,488
Ensembl chr 8:77,640,222...77,719,489
|
|
G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
decreases expression multiple interactions |
ISO |
sodium arsenate results in decreased expression of ALDH1A3 mRNA [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ALDH1A3 mRNA |
CTD |
PMID:12727804 PMID:32525701 |
|
NCBI chr 1:127,302,920...127,337,828
Ensembl chr 1:127,301,128...127,337,882
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
decreases expression |
ISO |
sodium arsenate results in decreased expression of ALDH2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr12:40,466,418...40,498,813
Ensembl chr12:40,466,495...40,498,752
|
|
G |
Aldh3b2 |
aldehyde dehydrogenase 3 family, member B2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ALDH3B2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 1:219,215,023...219,218,488
|
|
G |
Alg14 |
ALG14, UDP-N-acetylglucosaminyltransferase subunit |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ALG14 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 2:224,851,352...224,931,461
Ensembl chr 2:224,851,383...224,931,459
|
|
G |
Alg3 |
ALG3, alpha-1,3- mannosyltransferase |
increases expression |
ISO |
sodium arsenate results in increased expression of ALG3 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr11:83,985,484...83,991,706
Ensembl chr11:83,986,230...83,991,706
|
|
G |
Alkbh1 |
alkB homolog 1, histone H2A dioxygenase |
decreases expression |
ISO |
sodium arsenate results in decreased expression of NRP mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 6:111,456,096...111,476,829
Ensembl chr 6:111,456,187...111,477,090
|
|
G |
Alms1 |
ALMS1, centrosome and basal body associated protein |
increases expression |
ISO |
sodium arsenate results in increased expression of ALMS1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 4:117,371,544...117,472,310
Ensembl chr 4:117,371,659...117,472,198
|
|
G |
Alox12b |
arachidonate 12-lipoxygenase, 12R type |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ALOX12B mRNA |
CTD |
PMID:32525701 |
|
NCBI chr10:55,744,646...55,756,524
Ensembl chr10:55,744,588...55,756,566
|
|
G |
Aloxe3 |
arachidonate lipoxygenase 3 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ALOXE3 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr10:55,711,996...55,735,915
Ensembl chr10:55,712,043...55,735,911
|
|
G |
Ambra1 |
autophagy and beclin 1 regulator 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of AMBRA1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 3:80,634,470...80,830,068
Ensembl chr 3:80,634,470...80,830,068
|
|
G |
Amn1 |
antagonist of mitotic exit network 1 homolog |
increases expression |
ISO |
sodium arsenate results in increased expression of AMN1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 4:183,670,589...183,697,531
Ensembl chr 4:183,670,596...183,697,531
|
|
G |
Ank1 |
ankyrin 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of ANK1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr16:73,681,422...73,912,605
Ensembl chr16:73,681,422...73,827,488
|
|
G |
Ank3 |
ankyrin 3 |
decreases expression affects methylation increases expression |
ISO |
sodium arsenate results in decreased expression of ANK3 mRNA sodium arsenate affects the methylation of ANK3 promoter sodium arsenate results in increased expression of ANK3 mRNA |
CTD |
PMID:20667999 PMID:21795629 PMID:30953684 |
|
NCBI chr20:19,948,767...20,480,628
Ensembl chr20:20,105,047...20,480,623
|
|
G |
Ankhd1 |
ankyrin repeat and KH domain containing 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of ANKHD1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr18:29,386,906...29,485,611
Ensembl chr18:29,386,809...29,492,718
|
|
G |
Ankle2 |
ankyrin repeat and LEM domain containing 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of ANKLE2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr12:52,475,862...52,507,126
Ensembl chr12:52,475,863...52,507,126
|
|
G |
Ankrd10 |
ankyrin repeat domain 10 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of ANKRD10 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr16:83,205,898...83,229,147
Ensembl chr16:83,206,004...83,228,194
|
|
G |
Ankrd22 |
ankyrin repeat domain 22 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ANKRD22 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 1:252,430,750...252,461,346
Ensembl chr 1:252,429,677...252,461,461
|
|
G |
Ankrd37 |
ankyrin repeat domain 37 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ANKRD37 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr16:49,463,016...49,465,905
Ensembl chr16:49,462,889...49,465,888
|
|
G |
Ankrd44 |
ankyrin repeat domain 44 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of ANKRD44 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 9:61,229,252...61,529,532
Ensembl chr 9:61,231,988...61,528,882
|
|
G |
Ankrd49 |
ankyrin repeat domain 49 |
increases expression |
ISO |
sodium arsenate results in increased expression of ANKRD49 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 8:13,299,556...13,304,244
Ensembl chr 8:13,299,561...13,304,244
|
|
G |
Ankrd54 |
ankyrin repeat domain 54 |
increases expression |
ISO |
sodium arsenate results in increased expression of ANKRD54 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 7:120,282,423...120,295,647
Ensembl chr 7:120,282,822...120,295,618
|
|
G |
Anp32a |
acidic nuclear phosphoprotein 32 family member A |
increases expression |
ISO |
sodium arsenate results in increased expression of ANP32A mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 8:67,295,578...67,333,075
Ensembl chr 8:67,295,727...67,333,247
|
|
G |
Anpep |
alanyl aminopeptidase, membrane |
decreases expression |
ISO |
sodium arsenate results in decreased expression of ANPEP mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 1:141,561,364...141,604,249
Ensembl chr 1:141,561,334...141,604,273
|
|
G |
Anxa9 |
annexin A9 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ANXA9 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 2:196,470,318...196,481,568
Ensembl chr 2:196,470,858...196,479,770
|
|
G |
Aoc1 |
amine oxidase, copper containing 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of AOC1 mRNA |
CTD |
PMID:12727804 |
|
NCBI chr 4:78,496,043...78,515,582
Ensembl chr 4:78,496,043...78,515,584
|
|
G |
Aopep |
aminopeptidase O |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of AOPEP mRNA |
CTD |
PMID:32525701 |
|
NCBI chr17:507,389...825,062
Ensembl chr17:507,377...821,582
|
|
G |
Ap1m2 |
adaptor related protein complex 1 subunit mu 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of AP1M2 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 8:22,318,941...22,336,827
Ensembl chr 8:22,319,331...22,336,794
|
|
G |
Ap3s2 |
adaptor related protein complex 3 subunit sigma 2 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of AP3S2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 1:141,612,961...141,655,417
Ensembl chr 1:141,612,963...141,655,894
|
|
G |
Ap4e1 |
adaptor related protein complex 4 subunit epsilon 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of AP4E1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 3:119,484,714...119,548,491
Ensembl chr 3:119,484,677...119,548,621
|
|
G |
Apbb3 |
amyloid beta precursor protein binding family B member 3 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of APBB3 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr18:29,497,865...29,504,995
Ensembl chr18:29,497,863...29,504,995
|
|
G |
Apc |
APC regulator of WNT signaling pathway |
increases expression |
ISO |
sodium arsenate results in increased expression of APC mRNA |
CTD |
PMID:21795629 |
|
NCBI chr18:27,011,710...27,106,323
Ensembl chr18:27,047,382...27,105,531
|
|
G |
Apc2 |
APC regulator of WNT signaling pathway 2 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of APC2 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 7:12,258,468...12,280,459
Ensembl chr 7:12,258,468...12,275,609
|
|
G |
Apcdd1 |
APC down-regulated 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of APCDD1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr18:58,270,398...58,300,982
Ensembl chr18:58,270,410...58,301,002
|
|
G |
Aplnr |
apelin receptor |
increases expression |
ISO |
sodium arsenate results in increased expression of APLNR mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 3:72,540,538...72,544,183
Ensembl chr 3:72,540,538...72,544,182
|
|
G |
Apobec2 |
apolipoprotein B mRNA editing enzyme catalytic subunit 2 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of APOBEC2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 9:14,529,218...14,542,731
Ensembl chr 9:14,529,218...14,542,731
|
|
G |
Apold1 |
apolipoprotein L domain containing 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of APOLD1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 4:168,752,142...168,755,024
Ensembl chr 4:168,752,133...168,755,023
|
|
G |
Apom |
apolipoprotein M |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of APOM mRNA |
CTD |
PMID:32525701 |
|
NCBI chr20:5,120,473...5,123,073
Ensembl chr20:5,120,474...5,123,073
|
|
G |
Appbp2 |
amyloid beta precursor protein binding protein 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of APPBP2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr10:72,503,347...72,545,141
Ensembl chr10:72,503,347...72,545,141
|
|
G |
Appl1 |
adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of APPL1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr16:2,560,103...2,602,035
Ensembl chr16:2,563,520...2,602,103
|
|
G |
Appl2 |
adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of APPL2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 7:26,256,179...26,306,128
Ensembl chr 7:26,256,459...26,306,126
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
increases expression multiple interactions |
ISO |
sodium arsenate results in increased expression of AQP3 mRNA [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of AQP3 mRNA |
CTD |
PMID:21795629 PMID:32525701 |
|
NCBI chr 5:57,423,735...57,429,252
Ensembl chr 5:57,423,734...57,429,245
|
|
G |
Aqp9 |
aquaporin 9 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of AQP9 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 8:77,559,621...77,599,781
Ensembl chr 8:77,559,624...77,599,781
|
|
G |
Araf |
A-Raf proto-oncogene, serine/threonine kinase |
decreases expression |
ISO |
sodium arsenate results in decreased expression of ARAF mRNA |
CTD |
PMID:30953684 |
|
NCBI chr X:1,369,534...1,391,603
Ensembl chr X:1,379,194...1,390,873
|
|
G |
Arc |
activity-regulated cytoskeleton-associated protein |
decreases expression |
ISO |
sodium arsenate results in decreased expression of ARC mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 7:115,907,097...115,911,059
Ensembl chr 7:115,907,097...115,910,541
|
|
G |
Arf1 |
ADP-ribosylation factor 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ARF1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr10:45,562,700...45,579,214
Ensembl chr10:45,563,547...45,579,029
|
|
G |
Arg1 |
arginase 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ARG1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 1:21,525,421...21,537,872
Ensembl chr 1:21,525,421...21,537,863
|
|
G |
Arglu1 |
arginine and glutamate rich 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of ARGLU1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr16:86,600,877...86,625,084
Ensembl chr16:86,600,877...86,625,083
|
|
G |
Arhgap12 |
Rho GTPase activating protein 12 |
increases expression |
ISO |
sodium arsenate results in increased expression of ARHGAP12 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr17:54,280,815...54,394,716
Ensembl chr17:54,280,851...54,394,634
|
|
G |
Arhgap25 |
Rho GTPase activating protein 25 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ARHGAP25 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 4:119,249,682...119,327,822
Ensembl chr 4:119,249,682...119,327,822
|
|
G |
Arhgap31 |
Rho GTPase activating protein 31 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of ARHGAP31 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr11:64,600,968...64,714,114
Ensembl chr11:64,601,029...64,714,252
|
|
G |
Arhgdib |
Rho GDP dissociation inhibitor beta |
decreases expression |
ISO |
sodium arsenate results in decreased expression of ARHGDIB mRNA |
CTD |
PMID:12727804 |
|
NCBI chr 4:170,913,920...170,932,789
Ensembl chr 4:170,913,923...170,932,618
|
|
G |
Arhgef1 |
Rho guanine nucleotide exchange factor 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of ARHGEF1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 1:81,769,212...81,797,237
Ensembl chr 1:81,779,380...81,797,236
|
|
G |
Arhgef26 |
Rho guanine nucleotide exchange factor 26 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of ARHGEF26 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 2:27,107,263...27,236,336
Ensembl chr 2:27,107,318...27,236,672
|
|
G |
Arid2 |
AT-rich interaction domain 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of ARID2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 7:137,680,564...137,798,329
Ensembl chr 7:137,680,530...137,795,655
|
|
G |
Arid3b |
AT-rich interaction domain 3B |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ARID3B mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 8:62,569,601...62,616,837
Ensembl chr 8:62,569,528...62,616,828
|
|
G |
Arid4b |
AT-rich interaction domain 4B |
increases expression |
ISO |
sodium arsenate results in increased expression of ARID4B mRNA |
CTD |
PMID:21795629 |
|
NCBI chr17:53,831,353...53,955,897
Ensembl chr17:53,833,023...53,915,076 Ensembl chr17:53,833,023...53,915,076
|
|
G |
Arid5b |
AT-rich interaction domain 5B |
decreases expression multiple interactions |
ISO |
sodium arsenate results in decreased expression of ARID5B mRNA [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ARID5B mRNA |
CTD |
PMID:21795629 PMID:32525701 |
|
NCBI chr20:21,713,900...21,881,193
Ensembl chr20:21,564,975...21,880,715
|
|
G |
Arih1 |
ariadne RBR E3 ubiquitin protein ligase 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ARIH1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 8:64,166,359...64,268,555
Ensembl chr 8:64,166,360...64,268,555
|
|
G |
Arl16 |
ADP-ribosylation factor like GTPase 16 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of ARL16 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr10:109,636,770...109,639,018
Ensembl chr10:109,636,896...109,639,054
|
|
G |
Arl5a |
ADP-ribosylation factor like GTPase 5A |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ARL5A mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 3:37,922,544...37,947,434
Ensembl chr 3:37,924,793...37,947,283
|
|
G |
Arl6ip1 |
ADP-ribosylation factor like GTPase 6 interacting protein 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of ARL6IP1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 1:187,770,160...187,779,675
Ensembl chr 1:187,770,160...187,779,675
|
|
G |
Armc8 |
armadillo repeat containing 8 |
increases expression |
ISO |
sodium arsenate results in increased expression of ARMC8 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 8:107,723,359...107,819,208
Ensembl chr 8:107,723,359...107,819,050
|
|
G |
Armh1 |
armadillo-like helical domain containing 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ARMH1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 5:136,073,056...136,112,344
Ensembl chr 5:136,073,056...136,112,344
|
|
G |
Arpc2 |
actin related protein 2/3 complex, subunit 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of ARPC2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 9:81,518,163...81,548,871
Ensembl chr 9:81,518,176...81,548,871
|
|
G |
Arpc4 |
actin related protein 2/3 complex, subunit 4 |
increases expression |
ISO |
sodium arsenate results in increased expression of ARPC4 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 4:145,330,457...145,340,985
Ensembl chr 4:145,330,457...145,340,984
|
|
G |
Arrdc3 |
arrestin domain containing 3 |
increases expression |
ISO |
sodium arsenate results in increased expression of ARRDC3 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 2:8,732,907...8,745,445
Ensembl chr 2:8,732,932...8,743,069
|
|
G |
Asap1 |
ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ASAP1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 7:104,670,076...104,951,090
Ensembl chr 7:104,669,672...104,801,045
|
|
G |
Asap3 |
ArfGAP with SH3 domain, ankyrin repeat and PH domain 3 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ASAP3 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 5:154,551,901...154,596,125
Ensembl chr 5:154,552,195...154,594,785
|
|
G |
Asb13 |
ankyrin repeat and SOCS box-containing 13 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of ASB13 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr17:70,215,401...70,234,103
Ensembl chr17:70,215,401...70,234,103
|
|
G |
Ascl2 |
achaete-scute family bHLH transcription factor 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ASCL2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 1:216,154,002...216,156,409
Ensembl chr 1:216,154,002...216,156,409
|
|
G |
Ash1l |
ASH1 like histone lysine methyltransferase |
increases expression |
ISO |
sodium arsenate results in increased expression of ASH1L mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 2:188,252,592...188,389,251
Ensembl chr 2:188,253,220...188,389,250
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
ISO |
sodium arsenate results in increased expression of ASNS mRNA |
CTD |
PMID:12727804 |
|
NCBI chr 4:33,742,876...33,761,106
Ensembl chr 4:33,743,364...33,761,163
|
|
G |
Aspg |
asparaginase |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ASPG mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 6:136,682,279...136,701,673
Ensembl chr 6:136,682,126...136,701,628
|
|
G |
Asprv1 |
aspartic peptidase, retroviral-like 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ASPRV1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 4:118,431,755...118,433,286
Ensembl chr 4:118,431,755...118,432,775
|
|
G |
Atf2 |
activating transcription factor 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ATF2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 3:60,721,137...60,795,951
Ensembl chr 3:60,721,135...60,795,951
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression |
ISO |
sodium arsenate analog results in increased expression of ATF4 mRNA |
CTD |
PMID:23221991 |
|
NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
|
|
G |
Atg7 |
autophagy related 7 |
multiple interactions |
ISO |
ATG7 protein affects the reaction [[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of HMOX1 protein] |
CTD |
PMID:32525701 |
|
NCBI chr 4:146,570,113...146,777,093
Ensembl chr 4:146,598,413...146,777,124
|
|
G |
Atp10b |
ATPase phospholipid transporting 10B (putative) |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ATP10B mRNA |
CTD |
PMID:32525701 |
|
NCBI chr10:28,449,248...28,862,423
Ensembl chr10:28,449,335...28,864,255
|
|
G |
Atp12a |
ATPase H+/K+ transporting non-gastric alpha2 subunit |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ATP12A mRNA |
CTD |
PMID:32525701 |
|
NCBI chr15:36,561,306...36,590,171
Ensembl chr15:36,565,495...36,590,171
|
|
G |
Atp13a3 |
ATPase 13A3 |
increases expression |
ISO |
sodium arsenate results in increased expression of ATP13A3 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr11:73,936,750...73,963,852
Ensembl chr11:73,936,750...73,963,852
|
|
G |
Atp1b2 |
ATPase Na+/K+ transporting subunit beta 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of ATP1B2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr10:56,205,622...56,211,879
Ensembl chr10:56,205,625...56,211,891
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
increases expression decreases expression |
ISO |
sodium arsenate results in increased expression of ATP2A2 mRNA sodium arsenate results in decreased expression of ATP2A2 mRNA |
CTD |
PMID:21795629 PMID:30953684 |
|
NCBI chr12:39,553,903...39,603,326
Ensembl chr12:39,553,903...39,603,326
|
|
G |
Atp2b1 |
ATPase plasma membrane Ca2+ transporting 1 |
decreases expression increases expression |
ISO |
sodium arsenate results in decreased expression of ATP2B1 mRNA sodium arsenate results in increased expression of ATP2B1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 7:41,114,606...41,223,138
Ensembl chr 7:41,114,697...41,220,579
|
|
G |
Atp2b4 |
ATPase plasma membrane Ca2+ transporting 4 |
increases expression |
ISO |
sodium arsenate results in increased expression of ATP2B4 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr13:50,091,644...50,153,808
Ensembl chr13:50,091,430...50,153,823
|
|
G |
Atp2c1 |
ATPase secretory pathway Ca2+ transporting 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of ATP2C1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 8:113,953,959...114,039,965
Ensembl chr 8:113,955,647...114,013,623
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
increases expression |
ISO |
sodium arsenate results in increased expression of ATP5A1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr18:74,156,553...74,164,490
Ensembl chr18:74,156,553...74,164,495
|
|
G |
Atp6v0c |
ATPase H+ transporting V0 subunit C |
decreases expression |
ISO |
sodium arsenate results in decreased expression of ATP6V0C mRNA |
CTD |
PMID:30953684 |
|
NCBI chr10:13,537,031...13,543,407
Ensembl chr10:13,537,033...13,542,077
|
|
G |
Atp6v0e1 |
ATPase H+ transporting V0 subunit e1 |
increases expression |
ISO |
sodium arsenate results in increased expression of ATP6V0E mRNA |
CTD |
PMID:30953684 |
|
NCBI chr10:16,769,857...16,792,930
Ensembl chr10:16,769,666...16,792,909
|
|
G |
Atp6v0e2 |
ATPase, H+ transporting V0 subunit e2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ATP6V0E2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 4:78,168,117...78,171,265
Ensembl chr 4:78,168,117...78,171,265
|
|
G |
Atp6v1c2 |
ATPase H+ transporting V1 subunit C2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ATP6V1C2 mRNA; [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ATP6V1C2 protein |
CTD |
PMID:32525701 |
|
NCBI chr 6:42,585,452...42,632,289
Ensembl chr 6:42,585,934...42,630,983
|
|
G |
Atp7a |
ATPase copper transporting alpha |
increases expression |
ISO |
sodium arsenate results in increased expression of ATP7A mRNA |
CTD |
PMID:21795629 |
|
NCBI chr X:77,076,085...77,193,644
Ensembl chr X:77,076,106...77,193,644
|
|
G |
Atp8a1 |
ATPase phospholipid transporting 8A1 |
increases expression |
ISO |
sodium arsenate results in increased expression of ATP8A1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr14:41,972,398...42,210,555
Ensembl chr14:42,015,347...42,206,311
|
|
G |
Atxn1 |
ataxin 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of ATXN1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr17:19,160,986...19,533,814
Ensembl chr17:19,249,952...19,533,814
|
|
G |
Atxn2 |
ataxin 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of ATXN2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr12:40,264,601...40,335,637
Ensembl chr12:40,266,662...40,332,612
|
|
G |
Atxn2l |
ataxin 2-like |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ATXN2L mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 1:197,908,087...197,920,400
Ensembl chr 1:197,908,094...197,919,560
|
|
G |
Atxn7l3 |
ataxin 7-like 3 |
increases expression |
ISO |
sodium arsenate results in increased expression of ATXN7L3 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr10:90,234,749...90,241,757
Ensembl chr10:90,236,928...90,240,509
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
increases expression |
ISO |
sodium arsenate results in increased expression of AVPR1A mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 7:67,341,366...67,345,290
Ensembl chr 7:67,341,080...67,345,308
|
|
G |
Axl |
Axl receptor tyrosine kinase |
increases expression multiple interactions |
ISO |
sodium arsenate results in increased expression of AXL mRNA [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of AXL mRNA |
CTD |
PMID:30953684 PMID:32525701 |
|
NCBI chr 1:82,550,892...82,580,761
Ensembl chr 1:82,549,420...82,580,761
|
|
G |
Azgp1 |
alpha-2-glycoprotein 1, zinc-binding |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of AZGP1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr12:19,196,565...19,203,094
Ensembl chr12:19,196,611...19,202,647
|
|
G |
B4galt6 |
beta-1,4-galactosyltransferase 6 |
increases expression |
ISO |
sodium arsenate results in increased expression of B4GALT6 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr18:15,462,913...15,525,584
Ensembl chr18:15,462,913...15,525,579
|
|
G |
B9d1 |
B9 domain containing 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of B9D1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr10:47,784,294...47,794,399
Ensembl chr10:47,785,033...47,792,590 Ensembl chr10:47,785,033...47,792,590
|
|
G |
Bach1 |
BTB domain and CNC homolog 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of BACH1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr11:27,364,913...27,398,713
Ensembl chr11:27,364,916...27,398,842 Ensembl chr11:27,364,916...27,398,842
|
|
G |
Bag4 |
BAG cochaperone 4 |
increases expression |
ISO |
sodium arsenate results in increased expression of BAG4 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr16:71,057,709...71,075,874
Ensembl chr16:71,058,022...71,075,320
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
EXP |
sodium arsenate results in increased expression of BAX mRNA; sodium arsenate results in increased expression of BAX protein Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of BAX mRNA]; thymoquinone inhibits the reaction [sodium arsenate results in increased expression of BAX mRNA]; thymoquinone inhibits the reaction [sodium arsenate results in increased expression of BAX protein] |
CTD |
PMID:29710533 PMID:29854611 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Baz1a |
bromodomain adjacent to zinc finger domain, 1A |
increases expression |
ISO |
sodium arsenate results in increased expression of BAZ1A mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 6:75,793,223...75,873,854
Ensembl chr 6:75,793,960...75,874,235
|
|
G |
Bbip1 |
BBSome interacting protein 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of BBIP1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 1:274,649,085...274,663,544
Ensembl chr 1:274,649,490...274,650,363
|
|
G |
Bbox1 |
gamma-butyrobetaine hydroxylase 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of BBOX1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 3:101,425,684...101,474,848
Ensembl chr 3:101,427,055...101,474,890
|
|
G |
Bbx |
BBX high mobility group box domain containing |
increases expression |
ISO |
sodium arsenate results in increased expression of BBX mRNA |
CTD |
PMID:21795629 |
|
NCBI chr11:52,983,286...53,228,557
Ensembl chr11:53,081,025...53,228,716
|
|
G |
Bcar1 |
BCAR1 scaffold protein, Cas family member |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of BCAR1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr19:43,932,543...43,967,452
Ensembl chr19:43,932,554...43,955,783
|
|
G |
Bcar3 |
BCAR3 adaptor protein, NSP family member |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of BCAR3 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 2:226,563,050...226,679,449
Ensembl chr 2:226,563,050...226,679,438
|
|
G |
Bcat2 |
branched chain amino acid transaminase 2 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of BCAT2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 1:101,553,900...101,572,103
Ensembl chr 1:101,554,642...101,572,080
|
|
G |
Bche |
butyrylcholinesterase |
increases expression |
ISO |
sodium arsenate results in increased expression of BCHE mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 2:171,104,476...171,196,186
Ensembl chr 2:171,100,140...171,196,395
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression decreases expression multiple interactions |
ISO EXP |
sodium arsenate results in increased expression of BCL2 mRNA sodium arsenate results in decreased expression of BCL2 mRNA sodium arsenate results in decreased expression of BCL2 mRNA; sodium arsenate results in decreased expression of BCL2 protein Ellagic Acid inhibits the reaction [sodium arsenate results in decreased expression of BCL2 mRNA]; thymoquinone inhibits the reaction [sodium arsenate results in decreased expression of BCL2 mRNA] |
CTD |
PMID:21795629 PMID:29710533 PMID:29854611 PMID:30953684 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of BCL2L1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bcl6 |
BCL6, transcription repressor |
increases expression |
ISO |
sodium arsenate results in increased expression of BCL6 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr11:80,255,790...80,279,075
Ensembl chr11:80,255,790...80,279,075
|
|
G |
Bclaf1 |
BCL2-associated transcription factor 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of BCLAF1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 1:15,799,753...15,828,838
Ensembl chr 1:15,782,477...15,860,624
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions affects expression |
ISO |
Fluoxetine affects the reaction [sodium arsenate affects the expression of BDNF protein] |
CTD |
PMID:24952232 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Birc6 |
baculoviral IAP repeat-containing 6 |
decreases expression increases expression |
ISO |
sodium arsenate results in decreased expression of BIRC6 mRNA sodium arsenate results in increased expression of BIRC6 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 6:21,900,763...22,092,484
Ensembl chr 6:21,950,100...22,092,346
|
|
G |
Blmh |
bleomycin hydrolase |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of BLMH mRNA |
CTD |
PMID:32525701 |
|
NCBI chr10:63,197,367...63,240,447
Ensembl chr10:63,197,364...63,240,332
|
|
G |
Bmf |
Bcl2 modifying factor |
decreases expression |
ISO |
sodium arsenate results in decreased expression of BMF mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 3:110,303,515...110,324,125
Ensembl chr 3:110,306,067...110,324,084
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of BMP4 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr15:20,776,060...20,791,013
Ensembl chr15:20,776,054...20,822,740
|
|
G |
Bmp5 |
bone morphogenetic protein 5 |
increases expression |
ISO |
sodium arsenate results in increased expression of BMP5 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 8:82,669,466...82,950,273
Ensembl chr 8:82,878,941...82,950,273
|
|
G |
Bnc1 |
basonuclin 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of BNC1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 1:143,793,280...143,818,748 NCBI chr 1:143,869,440...143,878,077
Ensembl chr 1:143,793,064...143,818,706
|
|
G |
Bnipl |
BCL2 interacting protein like |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of BNIPL mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 2:196,415,736...196,425,727
Ensembl chr 2:196,415,738...196,425,727
|
|
G |
Bora |
bora, aurora kinase A activator |
decreases expression |
ISO |
sodium arsenate results in decreased expression of BORA mRNA |
CTD |
PMID:30953684 |
|
NCBI chr15:83,442,217...83,463,737
Ensembl chr15:83,442,144...83,463,717
|
|
G |
Bpifc |
BPI fold containing family C |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of BPIFC mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 7:23,854,846...23,911,953
Ensembl chr 7:23,854,846...23,911,953
|
|
G |
Bpnt1 |
3'(2'), 5'-bisphosphate nucleotidase 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of BPNT1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr13:103,268,045...103,292,848
Ensembl chr13:103,268,068...103,292,854
|
|
G |
Bpnt2 |
3'(2'), 5'-bisphosphate nucleotidase 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of BPNT2 mRNA |
CTD |
PMID:21795629 PMID:30953684 |
|
NCBI chr17:90,191,119...90,218,013
Ensembl chr17:90,188,043...90,218,013 Ensembl chr 5:90,188,043...90,218,013
|
|
G |
Bptf |
bromodomain PHD finger transcription factor |
decreases expression |
ISO |
sodium arsenate results in decreased expression of BPTF mRNA |
CTD |
PMID:30953684 |
|
NCBI chr10:95,248,573...95,350,162
Ensembl chr10:95,250,294...95,349,789
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
decreases expression increases expression |
ISO |
sodium arsenate results in decreased expression of BRAF mRNA sodium arsenate results in increased expression of BRAF mRNA |
CTD |
PMID:21795629 PMID:30953684 |
|
NCBI chr 4:67,389,331...67,520,549
Ensembl chr 4:67,396,192...67,520,356
|
|
G |
Brd8 |
bromodomain containing 8 |
decreases expression increases expression |
ISO |
sodium arsenate results in decreased expression of BRD8 mRNA sodium arsenate results in increased expression of BRD8 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr18:27,375,645...27,423,989
Ensembl chr18:27,398,688...27,424,090
|
|
G |
Brwd1 |
bromodomain and WD repeat domain containing 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of BRWD1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr11:36,338,080...36,430,473
Ensembl chr11:36,337,635...36,430,413
|
|
G |
Btbd7 |
BTB domain containing 7 |
increases expression |
ISO |
sodium arsenate results in increased expression of BTBD7 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 6:126,658,398...126,748,497
Ensembl chr 6:126,661,634...126,710,858
|
|
G |
Bves |
blood vessel epicardial substance |
increases expression |
ISO |
sodium arsenate results in increased expression of BVES mRNA |
CTD |
PMID:21795629 |
|
NCBI chr20:50,439,885...50,474,678
Ensembl chr20:50,439,883...50,474,678
|
|
G |
Bzw1 |
basic leucine zipper and W2 domains 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of BZW1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 9:65,279,675...65,293,471
Ensembl chr 9:65,279,675...65,291,651
|
|
G |
Bzw2 |
basic leucine zipper and W2 domains 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of BZW2 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 6:55,586,754...55,647,650
Ensembl chr 6:55,586,346...55,647,665
|
|
G |
C17h6orf52 |
similar to human chromosome 6 open reading frame 52 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of C6ORF52 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr17:21,600,326...21,615,888
Ensembl chr17:21,600,432...21,613,930
|
|
G |
C1ql3 |
complement C1q like 3 |
increases expression |
ISO |
sodium arsenate results in increased expression of C1QL3 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr17:80,314,186...80,320,681
Ensembl chr17:80,314,186...80,320,681
|
|
G |
C2cd4b |
C2 calcium-dependent domain containing 4B |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of C2CD4B mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 8:73,555,414...73,580,848
Ensembl chr 8:73,593,310...73,594,332
|
|
G |
C5 |
complement C5 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of C5 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 3:14,049,993...14,113,931 NCBI chr 3:14,206,466...14,229,141
Ensembl chr 3:14,049,995...14,229,080
|
|
G |
Cacna1c |
calcium voltage-gated channel subunit alpha1 C |
increases expression |
ISO |
sodium arsenate results in increased expression of CACNA1C mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 4:150,635,808...151,270,790
Ensembl chr 4:150,641,066...150,829,913
|
|
G |
Cacna2d1 |
calcium voltage-gated channel auxiliary subunit alpha2delta 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of CACNA2D1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 4:15,706,974...16,130,848
Ensembl chr 4:15,710,417...16,130,848
|
|
G |
Cacnb2 |
calcium voltage-gated channel auxiliary subunit beta 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of CACNB2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr17:81,673,862...82,019,219
Ensembl chr17:81,798,756...82,017,682
|
|
G |
Cacng8 |
calcium voltage-gated channel auxiliary subunit gamma 8 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CACNG8 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 1:64,330,106...64,350,338
Ensembl chr 1:64,330,106...64,350,338
|
|
G |
Cacybp |
calcyclin binding protein |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CACYBP mRNA |
CTD |
PMID:32525701 |
|
NCBI chr13:77,948,771...77,959,089
Ensembl chr13:77,948,771...77,959,110
|
|
G |
Cadps2 |
calcium dependent secretion activator 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of CADPS2 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 4:50,326,447...50,861,161
Ensembl chr 4:50,326,442...50,860,756
|
|
G |
Calb2 |
calbindin 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CALB2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr19:41,482,743...41,509,617
Ensembl chr19:41,482,728...41,509,658
|
|
G |
Cald1 |
caldesmon 1 |
decreases expression increases expression |
ISO |
sodium arsenate results in decreased expression of CALD1 mRNA sodium arsenate results in increased expression of CALD1 mRNA |
CTD |
PMID:21795629 PMID:30953684 |
|
NCBI chr 4:62,103,948...62,291,375
Ensembl chr 4:62,220,736...62,291,489
|
|
G |
Calml3 |
calmodulin-like 3 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CALML3 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr17:70,070,458...70,073,697
Ensembl chr17:70,072,156...70,073,530
|
|
G |
Calml5 |
calmodulin-like 5 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CALML5 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr17:70,044,956...70,045,886
|
|
G |
Camk2d |
calcium/calmodulin-dependent protein kinase II delta |
increases expression |
ISO |
sodium arsenate results in increased expression of CAMK2D mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 2:230,900,907...231,132,207
Ensembl chr 2:230,901,126...231,132,039
|
|
G |
Camk2g |
calcium/calmodulin-dependent protein kinase II gamma |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CAMK2G mRNA |
CTD |
PMID:12727804 |
|
NCBI chr15:3,936,721...3,995,740
Ensembl chr15:3,936,786...3,995,915 Ensembl chr15:3,936,786...3,995,915
|
|
G |
Canx |
calnexin |
increases expression |
ISO |
sodium arsenate results in increased expression of CANX mRNA |
CTD |
PMID:21795629 |
|
NCBI chr10:35,800,942...35,833,939
Ensembl chr10:35,800,942...35,833,861
|
|
G |
Cap2 |
cyclase associated actin cytoskeleton regulatory protein 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of CAP2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr17:18,441,614...18,592,866
Ensembl chr17:18,442,127...18,592,750
|
|
G |
Capns1 |
calpain, small subunit 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CAPNS1 mRNA |
CTD |
PMID:12727804 |
|
NCBI chr 1:91,058,528...91,064,880
Ensembl chr 1:88,652,446...88,657,845
|
|
G |
Capza2 |
capping actin protein of muscle Z-line subunit alpha 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of CAPZA2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 4:44,936,290...44,972,270
Ensembl chr 4:44,936,290...44,972,267
|
|
G |
Casc3 |
CASC3 exon junction complex subunit |
increases expression |
ISO |
sodium arsenate results in increased expression of CASC3 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr10:86,724,534...86,744,485
Ensembl chr10:86,724,427...86,745,927
|
|
G |
Casp1 |
caspase 1 |
increases expression multiple interactions |
ISO |
sodium arsenate results in increased expression of CASP1 protein [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CASP1 mRNA |
CTD |
PMID:11353140 PMID:32525701 |
|
NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
|
|
G |
Casp3 |
caspase 3 |
increases expression increases cleavage increases activity multiple interactions |
EXP |
sodium arsenate results in increased expression of CASP3 mRNA sodium arsenate results in increased cleavage of CASP3 protein sodium arsenate results in increased activity of CASP3 protein Ellagic Acid inhibits the reaction [sodium arsenate results in increased activity of CASP3 protein]; thymoquinone inhibits the reaction [sodium arsenate results in increased cleavage of CASP3 protein]; thymoquinone inhibits the reaction [sodium arsenate results in increased expression of CASP3 mRNA] |
CTD |
PMID:29710533 PMID:29854611 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Castor1 |
cytosolic arginine sensor for mTORC1 subunit 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CASTOR1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr14:84,447,552...84,457,396
Ensembl chr14:84,447,885...84,452,367
|
|
G |
Cat |
catalase |
decreases activity multiple interactions affects activity |
EXP ISO |
sodium arsenate results in decreased activity of CAT protein epigallocatechin gallate inhibits the reaction [sodium arsenate results in decreased activity of CAT protein] imidacloprid promotes the reaction [sodium arsenate results in decreased activity of CAT protein]; sodium arsenate promotes the reaction [imidacloprid results in decreased activity of CAT protein] sodium arsenate affects the activity of CAT protein |
CTD |
PMID:24095718 PMID:24562057 PMID:26446860 PMID:28879625 PMID:29040955 PMID:30033815 PMID:30144451 PMID:30456172 PMID:30503583 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cavin1 |
caveolae associated protein 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CAVIN1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr10:88,862,513...88,874,495
Ensembl chr10:88,860,733...88,874,528
|
|
G |
Cavin2 |
caveolae associated protein 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of CAVIN2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 9:55,244,136...55,256,153
Ensembl chr 9:55,243,255...55,256,340
|
|
G |
Cbl |
Cbl proto-oncogene |
increases expression decreases expression |
ISO |
sodium arsenate results in increased expression of CBL mRNA sodium arsenate results in decreased expression of CBL mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 8:48,481,256...48,564,775
Ensembl chr 8:48,489,036...48,564,722
|
|
G |
Cbr4 |
carbonyl reductase 4 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CBR4 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr16:31,944,328...31,972,553
Ensembl chr16:31,956,753...31,972,507
|
|
G |
Cbx1 |
chromobox 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CBX1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr10:84,656,698...84,677,112
Ensembl chr10:84,669,914...84,675,741
|
|
G |
Ccar2 |
cell cycle and apoptosis regulator 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of CCAR2 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr15:51,818,887...51,834,443
Ensembl chr15:51,818,897...51,834,030
|
|
G |
Ccdc3 |
coiled-coil domain containing 3 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CCDC3 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr17:76,991,722...77,093,515
Ensembl chr17:76,995,043...77,093,308
|
|
G |
Ccdc74a |
coiled-coil domain containing 74A |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CCDC74A mRNA |
CTD |
PMID:32525701 |
|
NCBI chr11:87,547,026...87,554,513
Ensembl chr11:87,549,059...87,553,336
|
|
G |
Ccdc88a |
coiled coil domain containing 88A |
increases expression |
ISO |
sodium arsenate results in increased expression of CCDC88A mRNA |
CTD |
PMID:21795629 |
|
NCBI chr14:113,771,093...113,936,376
Ensembl chr14:113,867,209...113,932,263
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CCL20 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 9:88,918,359...88,921,017
Ensembl chr 9:88,918,433...88,921,001
|
|
G |
Ccn1 |
cellular communication network factor 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CCN1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 2:251,529,354...251,532,312
Ensembl chr 2:251,529,354...251,532,312
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
ISO EXP |
sodium arsenate results in increased expression of CCND1 protein sodium arsenate results in increased expression of CCND1 mRNA; sodium arsenate results in increased expression of CCND1 protein |
CTD |
PMID:10873715 PMID:14713550 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccnjl |
cyclin J-like |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CCNJL mRNA |
CTD |
PMID:32525701 |
|
NCBI chr10:29,122,713...29,181,610
Ensembl chr10:29,123,273...29,182,568
|
|
G |
Ccnt2 |
cyclin T2 |
increases expression |
ISO |
sodium arsenate results in increased expression of CCNT2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr13:44,475,959...44,516,892
Ensembl chr13:44,475,970...44,515,739
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of CCR2 mRNA |
CTD |
PMID:30953684 |
|
|
|
G |
Ccser2 |
coiled-coil serine-rich protein 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of CCSER2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr16:14,090,547...14,210,512
Ensembl chr16:14,095,058...14,210,449
|
|
G |
Cct7 |
chaperonin containing TCP1 subunit 7 |
increases expression |
ISO |
sodium arsenate results in increased expression of CCT7 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 4:117,235,023...117,252,265
Ensembl chr 4:117,235,023...117,252,265
|
|
G |
Cd14 |
CD14 molecule |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CD14 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr18:29,560,341...29,562,290
Ensembl chr18:29,560,365...29,562,153
|
|
G |
Cd151 |
CD151 molecule (Raph blood group) |
increases expression |
ISO |
sodium arsenate results in increased expression of CD151 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 1:214,446,659...214,450,668
Ensembl chr 1:214,009,784...214,013,765 Ensembl chr 1:214,009,784...214,013,765
|
|
G |
Cd163 |
CD163 molecule |
increases expression |
ISO |
sodium arsenate results in increased expression of CD163 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 4:156,752,063...156,785,467
Ensembl chr 4:156,752,082...156,785,467
|
|
G |
Cd2 |
Cd2 molecule |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CD2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 2:203,666,706...203,680,073
Ensembl chr 2:203,666,637...203,680,083
|
|
G |
Cd2ap |
CD2-associated protein |
increases expression |
ISO |
sodium arsenate results in increased expression of CD2AP mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 9:20,794,680...20,858,438
Ensembl chr 9:20,765,296...20,858,504
|
|
G |
Cd34 |
CD34 molecule |
increases expression |
ISO |
sodium arsenate results in increased expression of CD34 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr13:113,691,842...113,711,259
Ensembl chr13:113,691,932...113,711,647
|
|
G |
Cd36 |
CD36 molecule |
decreases expression multiple interactions |
ISO |
sodium arsenate analog results in decreased expression of CD36 mRNA [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CD36 mRNA |
CTD |
PMID:23221991 PMID:32525701 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Cd53 |
Cd53 molecule |
increases expression |
ISO |
sodium arsenate results in increased expression of CD53 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 2:209,489,279...209,537,098
Ensembl chr 2:209,489,279...209,537,087
|
|
G |
Cd68 |
Cd68 molecule |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CD68 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr10:56,268,726...56,270,605
Ensembl chr10:56,268,720...56,270,640
|
|
G |
Cd86 |
CD86 molecule |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CD86 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr11:67,060,305...67,117,990
Ensembl chr11:67,082,193...67,118,795
|
|
G |
Cd93 |
CD93 molecule |
increases expression |
ISO |
sodium arsenate results in increased expression of CD93 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 3:142,778,798...142,783,774
Ensembl chr 3:142,778,770...142,783,774
|
|
G |
Cdc14a |
cell division cycle 14A |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CDC14A mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 2:219,302,577...219,458,345
Ensembl chr 2:219,302,577...219,458,271
|
|
G |
Cdc20 |
cell division cycle 20 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CDC20 mRNA |
CTD |
PMID:12727804 |
|
NCBI chr 5:137,260,728...137,264,931
Ensembl chr 5:137,260,739...137,265,015
|
|
G |
Cdc25a |
cell division cycle 25A |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CDC25A mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 8:117,953,223...117,971,552
Ensembl chr 8:117,953,444...117,971,519
|
|
G |
Cdc25b |
cell division cycle 25B |
multiple interactions decreases activity |
ISO |
[CDC25B protein co-treated with GLRX protein co-treated with GSR protein co-treated with Glutathione] results in increased reduction of sodium arsenate; [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CDC25B mRNA sodium arsenate results in decreased activity of CDC25B protein |
CTD |
PMID:20025242 PMID:32525701 |
|
NCBI chr 3:123,731,539...123,741,696
Ensembl chr 3:123,731,539...123,741,339
|
|
G |
Cdc25c |
cell division cycle 25C |
multiple interactions |
ISO |
[CDC25C protein co-treated with GLRX protein co-treated with GSR protein co-treated with Glutathione] results in increased reduction of sodium arsenate |
CTD |
PMID:20025242 |
|
NCBI chr18:27,528,768...27,550,316
Ensembl chr18:27,528,354...27,550,224
|
|
G |
Cdcp1 |
CUB domain containing protein 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of CDCP1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 8:132,260,007...132,296,661
Ensembl chr 8:132,260,029...132,296,661
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of CDH1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
|
|
G |
Cdk12 |
cyclin-dependent kinase 12 |
increases expression |
ISO |
sodium arsenate results in increased expression of CDK12 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr10:86,157,186...86,210,657
Ensembl chr10:86,157,608...86,222,707
|
|
G |
Cdk16 |
cyclin-dependent kinase 16 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CDK16 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr X:1,707,285...1,718,821
Ensembl chr X:1,707,289...1,718,637
|
|
G |
Cdk18 |
cyclin-dependent kinase 18 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CDK18 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr13:48,893,525...48,926,673
Ensembl chr13:48,893,412...48,927,483
|
|
G |
Cdk5 |
cyclin-dependent kinase 5 |
increases expression |
ISO |
sodium arsenate results in increased expression of CDK5 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 4:7,282,945...7,287,427
Ensembl chr 4:7,282,948...7,288,383
|
|
G |
Cdk9 |
cyclin-dependent kinase 9 |
increases expression |
ISO |
sodium arsenate results in increased expression of CDK9 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 3:11,742,269...11,747,117
Ensembl chr 3:11,742,266...11,747,113
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
EXP |
sodium arsenate results in increased expression of CDKN1B mRNA; sodium arsenate results in increased expression of CDKN1B protein |
CTD |
PMID:14713550 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
decreases expression increases methylation |
ISO |
sodium arsenate results in decreased expression of CDKN2A mRNA sodium arsenate results in increased methylation of CDKN2A gene |
CTD |
PMID:11825526 |
|
NCBI chr 5:107,823,323...107,832,405
Ensembl chr 5:107,823,330...107,841,175
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CDKN2B mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 5:107,834,353...107,857,428
Ensembl chr 5:107,845,951...107,858,104
|
|
G |
Cdr2 |
cerebellar degeneration-related protein 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CDR2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 1:190,889,698...190,914,606
Ensembl chr 1:190,889,701...190,914,610
|
|
G |
Cdr2l |
cerebellar degeneration-related protein 2-like |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CDR2L mRNA |
CTD |
PMID:32525701 |
|
NCBI chr10:103,934,364...103,948,318
Ensembl chr10:103,934,797...103,948,322
|
|
G |
Cdsn |
corneodesmosin |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CDSN mRNA |
CTD |
PMID:32525701 |
|
NCBI chr20:3,704,626...3,707,266
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of CEACAM1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 1:82,327,955...82,344,345
Ensembl chr 1:82,327,955...82,344,345
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CEBPA mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
increases expression decreases expression |
ISO |
sodium arsenate results in increased expression of CEBPD mRNA sodium arsenate results in decreased expression of CEBPD mRNA |
CTD |
PMID:21795629 |
|
NCBI chr11:89,008,008...89,009,146
Ensembl chr11:89,008,008...89,009,146
|
|
G |
Celf1 |
CUGBP, Elav-like family member 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CELF1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 3:79,768,900...79,844,548
Ensembl chr 3:79,823,945...79,842,082
|
|
G |
Cemip |
cell migration inducing hyaluronidase |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CEMIP mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 1:146,069,774...146,226,320
Ensembl chr 1:146,069,771...146,226,462
|
|
G |
Cenpm |
centromere protein M |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CENPM mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 7:123,464,615...123,476,336
Ensembl chr 7:123,464,490...123,476,238
|
|
G |
Cenpo |
centromere protein O |
increases expression |
ISO |
sodium arsenate results in increased expression of CENPO mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 6:28,648,804...28,663,527
Ensembl chr 6:28,649,638...28,663,233
|
|
G |
Cep192 |
centrosomal protein 192 |
increases expression |
ISO |
sodium arsenate results in increased expression of CEP192 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr18:63,572,084...63,656,302
Ensembl chr18:63,524,452...63,656,286
|
|
G |
Cers4 |
ceramide synthase 4 |
increases expression |
ISO |
sodium arsenate results in increased expression of CERS4 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr12:4,439,750...4,474,759
Ensembl chr12:4,439,750...4,474,729
|
|
G |
Cert1 |
ceramide transporter 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of CERT1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 2:27,365,145...27,469,797
Ensembl chr 2:27,365,148...27,469,779
|
|
G |
Ces4a |
carboxylesterase 4A |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CES4A mRNA |
CTD |
PMID:32525701 |
|
NCBI chr19:37,090,018...37,111,448
Ensembl chr19:37,090,056...37,107,872
|
|
G |
Cfap300 |
cilia and flagella associated protein 300 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CFAP300 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 8:6,218,391...6,236,438
Ensembl chr 8:6,218,393...6,235,967
|
|
G |
Cfb |
complement factor B |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CFB mRNA |
CTD |
PMID:32525701 |
|
NCBI chr20:4,536,206...4,542,073
Ensembl chr20:4,536,203...4,561,066 Ensembl chr20:4,536,203...4,561,066
|
|
G |
Cfl2 |
cofilin 2 |
decreases expression increases expression |
ISO |
sodium arsenate results in decreased expression of CFL2 mRNA sodium arsenate results in increased expression of CFL2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 6:75,759,140...75,763,185
Ensembl chr 6:75,759,140...75,763,185
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CFLAR mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
|
|
G |
Cggbp1 |
CGG triplet repeat binding protein 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CGGBP1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr11:1,896,166...1,915,603
Ensembl chr11:1,896,209...1,915,587
|
|
G |
Cgn |
cingulin |
increases expression multiple interactions |
ISO |
sodium arsenate results in increased expression of CGN mRNA [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CGN mRNA |
CTD |
PMID:30953684 PMID:32525701 |
|
NCBI chr 2:195,909,691...195,937,130
Ensembl chr 2:195,909,626...195,935,878
|
|
G |
Chchd3 |
coiled-coil-helix-coiled-coil-helix domain containing 3 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CHCHD3 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 4:60,080,536...60,358,592
Ensembl chr 4:60,080,538...60,358,562
|
|
G |
Chd8 |
chromodomain helicase DNA binding protein 8 |
increases expression |
ISO |
sodium arsenate results in increased expression of CHD8 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr15:28,612,932...28,672,574
Ensembl chr15:28,612,932...28,672,569
|
|
G |
Chd9 |
chromodomain helicase DNA binding protein 9 |
increases expression |
ISO |
sodium arsenate results in increased expression of CHD9 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr19:17,364,969...17,517,757
Ensembl chr19:17,366,828...17,494,585
|
|
G |
Chic1 |
cysteine-rich hydrophobic domain 1 |
increases expression decreases expression |
ISO |
sodium arsenate results in increased expression of CHIC1 mRNA sodium arsenate results in decreased expression of CHIC1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr X:74,205,649...74,250,613
Ensembl chr X:74,200,972...74,244,846
|
|
G |
Chka |
choline kinase alpha |
increases expression |
ISO |
sodium arsenate results in increased expression of CHKA mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 1:219,076,618...219,126,221
Ensembl chr 1:219,077,771...219,126,220
|
|
G |
Chordc1 |
cysteine and histidine rich domain containing 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CHORDC1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 8:17,421,552...17,445,513
Ensembl chr 8:17,421,557...17,446,165
|
|
G |
Chpt1 |
choline phosphotransferase 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of CHPT1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 7:29,019,518...29,070,928
Ensembl chr 7:29,043,916...29,070,928
|
|
G |
Chrdl1 |
chordin-like 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of CHRDL1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr X:114,554,359...114,658,975
Ensembl chr X:114,554,359...114,658,931
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
increases expression |
ISO |
sodium arsenate results in increased expression of CHUK mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 1:263,848,829...263,884,354
Ensembl chr 1:263,848,884...263,885,169
|
|
G |
Cilk1 |
ciliogenesis associated kinase 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CILK1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 8:85,413,998...85,473,374
Ensembl chr 8:85,413,537...85,472,694
|
|
G |
Cinp |
cyclin-dependent kinase 2-interacting protein |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CINP mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 6:135,290,528...135,304,422
Ensembl chr 6:135,290,530...135,304,422
|
|
G |
Cirbp |
cold inducible RNA binding protein |
increases expression |
ISO |
sodium arsenate results in increased expression of CIRBP mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 7:12,400,066...12,405,054
Ensembl chr 7:12,401,207...12,405,022
|
|
G |
Cited4 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CITED4 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 5:139,597,731...139,598,622
Ensembl chr 5:139,597,731...139,598,622
|
|
G |
Ckm |
creatine kinase, M-type |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CKM mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 1:80,321,507...80,331,841
Ensembl chr 1:80,321,585...80,331,841
|
|
G |
Cks2 |
CDC28 protein kinase regulatory subunit 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CKS2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr17:13,587,664...13,593,423
Ensembl chr17:13,587,665...13,593,423
|
|
G |
Clba1 |
clathrin binding box of aftiphilin containing 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CLBA1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 6:137,386,694...137,393,490
Ensembl chr 6:137,386,422...137,393,506
|
|
G |
Clcf1 |
cardiotrophin-like cytokine factor 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CLCF1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 1:219,468,866...219,472,445
Ensembl chr 1:219,468,675...219,472,654
|
|
G |
Clcn3 |
chloride voltage-gated channel 3 |
increases expression |
ISO |
sodium arsenate results in increased expression of CLCN3 mRNA |
CTD |
PMID:21795629 PMID:30953684 |
|
NCBI chr16:32,448,821...32,520,649
Ensembl chr16:32,449,116...32,519,148
|
|
G |
Cldn1 |
claudin 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CLDN1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr11:77,815,216...77,830,373
Ensembl chr11:77,815,181...77,830,416
|
|
G |
Cldn23 |
claudin 23 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CLDN23 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr16:59,988,603...59,990,327
Ensembl chr16:59,988,603...59,990,326
|
|
G |
Cldn5 |
claudin 5 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CLDN5 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr11:86,356,292...86,357,718
Ensembl chr11:86,356,294...86,357,718
|
|
G |
Clec3b |
C-type lectin domain family 3, member B |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CLEC3B mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 8:132,241,016...132,248,066
Ensembl chr 8:132,241,134...132,246,694
|
|
G |
Clic5 |
chloride intracellular channel 5 |
increases expression |
ISO |
sodium arsenate results in increased expression of CLIC5 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 9:19,121,676...19,372,673
Ensembl chr 9:19,121,677...19,372,673
|
|
G |
Clk4 |
CDC-like kinase 4 |
increases expression |
ISO |
sodium arsenate results in increased expression of CLK4 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr10:36,715,565...36,733,473
Ensembl chr10:36,715,565...36,733,133
|
|
G |
Clock |
clock circadian regulator |
increases expression |
ISO |
sodium arsenate results in increased expression of CLOCK mRNA |
CTD |
PMID:21795629 |
|
NCBI chr14:34,418,226...34,502,218
Ensembl chr14:34,446,616...34,502,218
|
|
G |
Clpx |
caseinolytic mitochondrial matrix peptidase chaperone subunit X |
increases expression |
ISO |
sodium arsenate results in increased expression of CLPX mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 8:70,789,137...70,843,133
Ensembl chr 8:70,789,256...70,843,123
|
|
G |
Cmbl |
carboxymethylenebutenolidase homolog |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CMBL mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 2:84,645,084...84,666,836
Ensembl chr 2:84,645,084...84,666,835
|
|
G |
Cmtm4 |
CKLF-like MARVEL transmembrane domain containing 4 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CMTM4 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr19:784,618...824,420
Ensembl chr19:784,618...824,420
|
|
G |
Cmtm7 |
CKLF-like MARVEL transmembrane domain containing 7 |
decreases expression multiple interactions |
ISO |
sodium arsenate results in decreased expression of CMTM7 mRNA [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CMTM7 mRNA |
CTD |
PMID:30953684 PMID:32525701 |
|
NCBI chr 8:122,814,563...122,841,479
Ensembl chr 8:122,812,459...122,841,477
|
|
G |
Cmya5 |
cardiomyopathy associated 5 |
increases expression |
ISO |
sodium arsenate results in increased expression of CMYA5 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 2:22,646,694...22,744,536
Ensembl chr 2:22,646,712...22,744,407
|
|
G |
Cnfn |
cornifelin |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CNFN mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 1:82,234,032...82,236,602
Ensembl chr 1:82,234,032...82,236,179
|
|
G |
Cnot10 |
CCR4-NOT transcription complex, subunit 10 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CNOT10 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 8:122,634,681...122,696,466
Ensembl chr 8:122,634,685...122,679,720
|
|
G |
Cnot2 |
CCR4-NOT transcription complex, subunit 2 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CNOT2 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 7:59,526,105...59,617,307
Ensembl chr 7:59,527,124...59,587,385
|
|
G |
Cnot6l |
CCR4-NOT transcription complex, subunit 6-like |
increases expression |
ISO |
sodium arsenate results in increased expression of CNOT6L mRNA |
CTD |
PMID:30953684 |
|
NCBI chr14:15,059,101...15,148,255
Ensembl chr14:15,059,387...15,146,586
|
|
G |
Cntfr |
ciliary neurotrophic factor receptor |
increases expression |
ISO |
sodium arsenate results in increased expression of CNTFR mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 5:58,041,114...58,078,687
Ensembl chr 5:58,041,146...58,078,545
|
|
G |
Cntnap2 |
contactin associated protein 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CNTNAP2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 4:74,700,539...77,025,463
|
|
G |
Col12a1 |
collagen type XII alpha 1 chain |
increases expression |
ISO |
sodium arsenate results in increased expression of COL12A1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 8:87,042,820...87,150,701
Ensembl chr 8:87,040,799...87,158,368
|
|
G |
Col18a1 |
collagen type XVIII alpha 1 chain |
increases expression |
ISO |
sodium arsenate results in increased expression of COL18A1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr20:12,225,202...12,332,858
Ensembl chr20:12,225,202...12,332,858
|
|
G |
Col19a1 |
collagen type XIX alpha 1 chain |
increases expression |
ISO |
sodium arsenate results in increased expression of COL19A1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 9:30,508,003...30,864,836
Ensembl chr 9:30,515,089...30,844,199
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
sodium arsenate results in increased expression of COL1A1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
decreases expression multiple interactions increases expression |
ISO |
sodium arsenate results in decreased expression of COL1A2 mRNA [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of COL1A2 mRNA sodium arsenate results in increased expression of COL1A2 mRNA |
CTD |
PMID:21795629 PMID:32525701 |
|
NCBI chr 4:31,534,225...31,569,152
Ensembl chr 4:31,534,225...31,569,151
|
|
G |
Col22a1 |
collagen type XXII alpha 1 chain |
decreases expression |
ISO |
sodium arsenate results in decreased expression of COL22A1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 7:113,014,896...113,251,165
Ensembl chr 7:113,015,747...113,228,439
|
|
G |
Col25a1 |
collagen type XXV alpha 1 chain |
increases expression |
ISO |
sodium arsenate results in increased expression of COL25A1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 2:235,515,364...235,705,448
Ensembl chr 2:235,596,123...235,715,057
|
|
G |
Col4a6 |
collagen type IV alpha 6 chain |
increases expression |
ISO |
sodium arsenate results in increased expression of COL4A6 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr X:112,405,647...112,768,337
Ensembl chr X:112,405,647...112,473,822
|
|
G |
Col5a2 |
collagen type V alpha 2 chain |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of COL5A2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 9:52,091,088...52,238,735
Ensembl chr 9:52,092,511...52,238,564
|
|
G |
Col8a1 |
collagen type VIII alpha 1 chain |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of COL8A1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr11:44,877,690...45,006,203
Ensembl chr11:44,877,859...45,007,891
|
|
G |
Col8a2 |
collagen type VIII alpha 2 chain |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of COL8A2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 5:144,308,527...144,335,142
Ensembl chr 5:144,308,611...144,335,172
|
|
G |
Commd3 |
COMM domain containing 3 |
increases expression |
ISO |
sodium arsenate results in increased expression of COMMD3 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr17:85,356,042...85,359,835
Ensembl chr17:85,356,042...85,359,833
|
|
G |
Comtd1 |
catechol-O-methyltransferase domain containing 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of COMTD1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr15:2,631,529...2,634,640
Ensembl chr15:2,631,529...2,634,640
|
|
G |
Copb2 |
COPI coat complex subunit beta 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of COPB2 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 8:106,582,339...106,603,763
|
|
G |
Copg1 |
COPI coat complex subunit gamma 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of COPG1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 4:119,815,041...119,840,997
Ensembl chr 4:119,815,139...119,864,114
|
|
G |
Coro1c |
coronin 1C |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CORO1C mRNA |
CTD |
PMID:21795629 |
|
NCBI chr12:48,481,741...48,554,054
Ensembl chr12:48,481,750...48,554,052
|
|
G |
Cox15 |
cytochrome c oxidase assembly homolog COX15 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of COX15 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 1:263,494,850...263,511,510
Ensembl chr 1:263,494,852...263,511,505
|
|
G |
Cox8c |
cytochrome c oxidase subunit 8C |
increases expression |
ISO |
sodium arsenate results in increased expression of COX8C mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 6:126,766,967...126,768,290
Ensembl chr 6:126,766,967...126,768,290
|
|
G |
Cpd |
carboxypeptidase D |
increases expression |
ISO |
sodium arsenate results in increased expression of CPD mRNA |
CTD |
PMID:21795629 |
|
NCBI chr10:63,325,764...63,389,811
Ensembl chr10:63,325,199...63,389,817
|
|
G |
Cpe |
carboxypeptidase E |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CPE mRNA |
CTD |
PMID:32525701 |
|
NCBI chr16:26,906,716...27,014,811
Ensembl chr16:26,906,716...27,014,813
|
|
G |
Cpeb2 |
cytoplasmic polyadenylation element binding protein 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of CPEB2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr14:72,327,929...72,382,519
Ensembl chr14:72,331,705...72,380,330
|
|
G |
Cpeb4 |
cytoplasmic polyadenylation element binding protein 4 |
increases expression |
ISO |
sodium arsenate results in increased expression of CPEB4 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr10:15,984,520...16,047,209
Ensembl chr10:15,987,921...16,046,033
|
|
G |
Cpne3 |
copine 3 |
increases expression |
ISO |
sodium arsenate results in increased expression of CPNE3 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 5:33,525,307...33,574,610
Ensembl chr 5:33,528,154...33,574,596
|
|
G |
Cpne8 |
copine 8 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CPNE8 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 7:131,623,180...131,798,236
Ensembl chr 7:131,623,181...131,798,236
|
|
G |
Cps1 |
carbamoyl-phosphate synthase 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CPS1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 9:74,113,437...74,236,274
Ensembl chr 9:74,124,016...74,236,274
|
|
G |
Cpsf6 |
cleavage and polyadenylation specific factor 6 |
increases expression decreases expression |
ISO |
sodium arsenate results in increased expression of CPSF6 mRNA sodium arsenate results in decreased expression of CPSF6 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 7:60,385,688...60,417,661
Ensembl chr 7:60,385,688...60,416,925
|
|
G |
Cr1l |
complement C3b/C4b receptor 1 like |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CR1L mRNA |
CTD |
PMID:30953684 |
|
NCBI chr13:113,824,886...113,872,097
Ensembl chr13:113,824,892...113,872,097
|
|
G |
Crabp2 |
cellular retinoic acid binding protein 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CRABP2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 2:187,322,416...187,326,794
Ensembl chr 2:184,882,969...184,883,505
|
|
G |
Cracdl |
CRACD like |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CRACDL mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 9:44,194,348...44,309,816
Ensembl chr 9:44,194,325...44,237,117
|
|
G |
Cramp1 |
cramped chromatin regulator homolog 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CRAMP1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr10:14,324,799...14,373,413
Ensembl chr10:14,326,802...14,373,334
|
|
G |
Crcp |
CGRP receptor component |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CRCP mRNA |
CTD |
PMID:32525701 |
|
NCBI chr12:30,125,237...30,160,857
Ensembl chr12:30,125,168...30,180,115
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
affects expression increases expression multiple interactions |
ISO |
sodium arsenate affects the expression of CREB1 protein sodium arsenate results in increased expression of CREB1 mRNA Fluoxetine affects the reaction [sodium arsenate affects the expression of CREB1 protein] |
CTD |
PMID:21795629 PMID:24952232 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Creb3l1 |
cAMP responsive element binding protein 3-like 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CREB3L1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 3:80,892,433...80,933,283
Ensembl chr 3:80,892,435...80,933,283
|
|
G |
Crebrf |
CREB3 regulatory factor |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CREBRF mRNA |
CTD |
PMID:32525701 |
|
NCBI chr10:16,693,846...16,753,162
Ensembl chr10:16,694,792...16,752,205
|
|
G |
Crh |
corticotropin releasing hormone |
increases expression |
ISO |
sodium arsenate results in increased expression of CRH protein |
CTD |
PMID:22960421 |
|
NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
|
|
G |
Crip1 |
cysteine rich protein 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CRIP1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 6:137,959,171...137,967,042
Ensembl chr 6:137,959,171...137,967,042
|
|
G |
Crispld2 |
cysteine-rich secretory protein LCCL domain containing 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CRISPLD2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr19:52,647,038...52,705,118
Ensembl chr19:52,647,070...52,705,131
|
|
G |
Crk |
CRK proto-oncogene, adaptor protein |
increases expression |
ISO |
sodium arsenate results in increased expression of CRK mRNA |
CTD |
PMID:30953684 |
|
NCBI chr10:63,829,731...63,855,999
Ensembl chr10:63,829,807...63,852,780
|
|
G |
Crnn |
cornulin |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CRNN mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 2:193,427,097...193,432,070
Ensembl chr 2:193,429,176...193,431,487
|
|
G |
Crybg3 |
crystallin beta-gamma domain containing 3 |
increases expression |
ISO |
sodium arsenate results in increased expression of CRYBG3 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr11:42,895,610...43,006,568
Ensembl chr11:42,945,084...43,005,097
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CSF2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
|
|
G |
Csgalnact2 |
chondroitin sulfate N-acetylgalactosaminyltransferase 2 |
increases expression multiple interactions |
ISO |
sodium arsenate results in increased expression of CSGALNACT2 mRNA [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CSGALNACT2 mRNA |
CTD |
PMID:21795629 PMID:32525701 |
|
NCBI chr 4:150,148,626...150,185,062
Ensembl chr 4:150,153,844...150,185,044
|
|
G |
Csnk1a1 |
casein kinase 1, alpha 1 |
decreases expression increases expression |
ISO |
sodium arsenate results in decreased expression of CSNK1A1 mRNA sodium arsenate results in increased expression of CSNK1A1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr18:56,887,722...56,910,610
Ensembl chr18:56,887,354...56,918,345
|
|
G |
Csnk1g1 |
casein kinase 1, gamma 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of CSNK1G1 mRNA |
CTD |
PMID:21795629 PMID:30953684 |
|
NCBI chr 8:71,533,372...71,688,483
Ensembl chr 8:71,547,468...71,679,666
|
|
G |
Cspg4 |
chondroitin sulfate proteoglycan 4 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CSPG4 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 8:61,532,465...61,567,510
Ensembl chr 8:61,532,465...61,567,510
|
|
G |
Csrnp1 |
cysteine and serine rich nuclear protein 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CSRNP1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 8:128,659,883...128,673,339
Ensembl chr 8:128,659,868...128,672,284
|
|
G |
Csrp1 |
cysteine and glycine-rich protein 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of CSRP1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr13:52,553,843...52,575,054
Ensembl chr13:52,553,775...52,575,051
|
|
G |
Csrp2 |
cysteine and glycine-rich protein 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CSRP2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 7:53,630,675...53,649,309
Ensembl chr 7:53,630,621...53,649,310
|
|
G |
Cst6 |
cystatin E/M |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CST6 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 1:220,727,292...220,729,000
Ensembl chr 1:220,727,292...220,729,000
|
|
G |
Ctnnal1 |
catenin alpha-like 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CTNNAL1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 5:73,561,249...73,621,070
Ensembl chr 5:73,561,450...73,621,070
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression |
EXP |
sodium arsenate results in decreased expression of CTNNB1 mRNA; sodium arsenate results in decreased expression of CTNNB1 protein |
CTD |
PMID:14713550 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Ctsb |
cathepsin B |
decreases expression multiple interactions |
ISO |
sodium arsenate results in decreased expression of CTSB mRNA [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CTSB mRNA |
CTD |
PMID:21795629 PMID:32525701 |
|
NCBI chr15:46,316,741...46,337,613
Ensembl chr15:46,316,741...46,337,612
|
|
G |
Ctsd |
cathepsin D |
increases expression |
ISO |
sodium arsenate results in increased expression of CTSD mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 1:215,541,570...215,553,446
Ensembl chr 1:215,541,542...215,553,451
|
|
G |
Ctsh |
cathepsin H |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CTSH mRNA |
CTD |
PMID:12727804 |
|
NCBI chr 8:97,439,155...97,458,293
Ensembl chr 8:97,439,161...97,458,287
|
|
G |
Ctxn1 |
cortexin 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CTXN1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr12:2,534,212...2,535,823
Ensembl chr12:2,534,212...2,535,822
|
|
G |
Cul5 |
cullin 5 |
increases expression |
ISO |
sodium arsenate results in increased expression of CUL5 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 8:58,199,992...58,255,149
Ensembl chr 8:58,202,821...58,253,688
|
|
G |
Cux1 |
cut-like homeobox 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of CUX1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr12:23,150,886...23,470,095
Ensembl chr12:23,151,180...23,445,074
|
|
G |
Cux2 |
cut-like homeobox 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of CUX2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr12:40,016,774...40,221,067
Ensembl chr12:40,018,937...40,219,291
|
|
G |
Cwh43 |
cell wall biogenesis 43 C-terminal homolog |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CWH43 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr14:37,315,479...37,361,728
Ensembl chr14:37,315,406...37,361,798
|
|
G |
Cxcl14 |
C-X-C motif chemokine ligand 14 |
increases expression |
ISO |
sodium arsenate results in increased expression of CXCL14 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr17:9,109,731...9,117,754
Ensembl chr17:9,109,731...9,117,750
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of CXCL2 protein |
CTD |
PMID:11353140 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cxxc5 |
CXXC finger protein 5 |
increases expression |
ISO |
sodium arsenate results in increased expression of CXXC5 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr18:28,626,386...28,656,916
Ensembl chr18:28,653,592...28,656,937
|
|
G |
Cyb561 |
cytochrome b-561 |
increases expression |
ISO |
sodium arsenate results in increased expression of CYB561 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr10:94,136,993...94,147,567
Ensembl chr10:94,136,993...94,147,621
|
|
G |
Cyb5a |
cytochrome b5 type A |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CYB5A mRNA |
CTD |
PMID:32525701 |
|
NCBI chr18:81,694,818...81,726,821
Ensembl chr18:81,694,808...81,726,821
|
|
G |
Cyb5d2 |
cytochrome b5 domain containing 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CYB5D2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr10:59,343,347...59,360,979
Ensembl chr10:59,344,470...59,360,661
|
|
G |
Cyfip2 |
cytoplasmic FMR1 interacting protein 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CYFIP2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr10:31,278,746...31,419,235
Ensembl chr10:31,278,746...31,419,235
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases expression multiple interactions |
ISO |
sodium arsenate results in decreased expression of CYP1B1 mRNA [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CYP1B1 mRNA |
CTD |
PMID:11353140 PMID:32525701 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CYP2C18 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 1:258,074,797...258,139,176
Ensembl chr 1:258,074,860...258,139,176
|
|
G |
Cyp2f4 |
cytochrome P450, family 2, subfamily f, polypeptide 4 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CYP2F2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 1:83,933,974...83,947,804
Ensembl chr 1:83,933,942...83,947,821
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CYP3A5 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr12:19,074,288...19,114,491
Ensembl chr12:19,074,583...19,114,399
|
|
G |
Cyp4f1 |
cytochrome P450, family 4, subfamily f, polypeptide 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CYP4F12 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 7:15,179,472...15,191,113
Ensembl chr 7:15,179,467...15,190,796
|
|
G |
Cyp4f39 |
cytochrome P450, family 4, subfamily f, polypeptide 39 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CYP4F22 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 7:14,435,024...14,514,960
Ensembl chr 7:14,441,476...14,515,212
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:11353140 |
|
NCBI chr 2:102,701,903...102,871,257
Ensembl chr 2:102,701,903...102,871,257
|
|
G |
Cyria |
CYFIP related Rac1 interactor A |
increases expression |
ISO |
sodium arsenate results in increased expression of CYRIA mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 6:37,555,167...37,661,196
Ensembl chr 6:37,555,182...37,665,064
|
|
G |
Cysrt1 |
cysteine rich tail 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CYSRT1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 3:2,458,295...2,462,037
Ensembl chr 3:2,458,295...2,459,385
|
|
G |
Cyyr1 |
cysteine and tyrosine rich 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CYYR1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr11:24,967,936...25,078,740
Ensembl chr11:24,967,937...25,078,740
|
|
G |
Daam1 |
dishevelled associated activator of morphogenesis 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of DAAM1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 6:94,606,675...94,739,026
Ensembl chr 6:94,636,222...94,739,026
|
|
G |
Dapk1 |
death associated protein kinase 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of DAPK1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr17:4,297,038...4,454,941
Ensembl chr17:4,297,224...4,454,778
|
|
G |
Dbi |
diazepam binding inhibitor, acyl-CoA binding protein |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of DBI mRNA |
CTD |
PMID:32525701 |
|
NCBI chr13:36,147,667...36,156,076
Ensembl chr13:36,117,119...36,174,908
|
|
G |
Dbp |
D-box binding PAR bZIP transcription factor |
decreases expression |
ISO |
sodium arsenate results in decreased expression of DBP mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 1:101,687,896...101,692,845
Ensembl chr 1:101,687,855...101,692,846
|
|
G |
Dcaf12l1 |
DDB1 and CUL4 associated factor 12-like 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of DCAF12L1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr X:131,340,045...131,344,038
Ensembl chr X:131,340,045...131,343,853
|
|
G |
Dcakd |
dephospho-CoA kinase domain containing |
decreases expression |
ISO |
sodium arsenate results in decreased expression of DCAKD mRNA |
CTD |
PMID:30953684 |
|
NCBI chr10:91,095,601...91,126,733
Ensembl chr10:91,095,545...91,122,018
|
|
G |
Dcbld2 |
discoidin, CUB and LCCL domain containing 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of DCBLD2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr11:44,237,814...44,292,884
Ensembl chr11:44,241,111...44,292,884
|
|
G |
Dcp1a |
decapping mRNA 1A |
increases phosphorylation |
ISO |
sodium arsenate results in increased phosphorylation of DCP1A protein |
CTD |
PMID:19084008 |
|
NCBI chr16:6,542,415...6,583,856
Ensembl chr16:6,542,216...6,587,619
|
|
G |
Dctn4 |
dynactin subunit 4 |
increases expression |
ISO |
sodium arsenate results in increased expression of DCTN4 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr18:55,797,188...55,824,195
Ensembl chr18:55,797,198...55,822,036
|
|
G |
Dcun1d1 |
defective in cullin neddylation 1 domain containing 1 |
increases expression decreases expression |
ISO |
sodium arsenate results in increased expression of DCUN1D1 mRNA sodium arsenate results in decreased expression of DCUN1D1 mRNA |
CTD |
PMID:21795629 PMID:30953684 |
|
NCBI chr 2:122,476,173...122,527,153
Ensembl chr 2:122,476,173...122,646,445
|
|
G |
Dcx |
doublecortin |
affects expression |
ISO |
sodium arsenate affects the expression of DCX protein |
CTD |
PMID:27751817 |
|
NCBI chr X:115,098,675...115,175,515
Ensembl chr X:115,098,675...115,175,299
|
|
G |
Ddi2 |
DNA damage inducible 1 homolog 2 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of DDI2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 5:160,230,958...160,282,836
Ensembl chr 5:160,230,955...160,282,810
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
sodium arsenate results in increased expression of DDIT3 mRNA sodium arsenate analog results in increased expression of DDIT3 mRNA; sodium arsenate analog results in increased expression of DDIT3 protein |
CTD |
PMID:12727804 PMID:23221991 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Ddr2 |
discoidin domain receptor tyrosine kinase 2 |
decreases expression increases expression |
ISO |
sodium arsenate results in decreased expression of DDR2 mRNA sodium arsenate results in increased expression of DDR2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr13:88,311,639...88,436,561
Ensembl chr13:88,317,145...88,436,789
|
|
G |
Ddx11 |
DEAD/H-box helicase 11 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of DDX11 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 9:114,113,642...114,133,908
Ensembl chr 9:114,111,580...114,132,492
|
|
G |
Ddx58 |
DEXD/H-box helicase 58 |
increases expression |
ISO |
sodium arsenate results in increased expression of DDX58 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 5:56,486,584...56,536,898
Ensembl chr 5:56,500,734...56,536,772
|
|
G |
Ddx6 |
DEAD-box helicase 6 |
decreases expression increases expression |
ISO |
sodium arsenate results in decreased expression of DDX6 mRNA sodium arsenate results in increased expression of DDX6 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 8:48,924,768...48,961,394
Ensembl chr 8:48,925,604...48,958,026
|
|
G |
Defb1 |
defensin beta 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of DEFB1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr16:75,294,385...75,309,127
Ensembl chr16:75,294,376...75,309,176
|
|
G |
Degs1 |
delta(4)-desaturase, sphingolipid 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of DEGS1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr13:100,665,265...100,672,731
Ensembl chr13:100,666,075...100,672,731
|
|
G |
Dennd1b |
DENN domain containing 1B |
decreases expression |
ISO |
sodium arsenate results in decreased expression of DENND1B mRNA |
CTD |
PMID:21795629 |
|
NCBI chr13:56,015,813...56,242,041
Ensembl chr13:56,015,901...56,236,677
|
|
G |
Dennd2d |
DENN domain containing 2D |
increases expression |
ISO |
sodium arsenate results in increased expression of DENND2D mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 2:209,097,894...209,116,978
Ensembl chr 2:209,097,927...209,116,965
|
|
G |
Dennd3 |
DENN domain containing 3 |
increases expression |
ISO |
sodium arsenate results in increased expression of DENND3 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 7:114,724,644...114,812,471
Ensembl chr 7:114,724,610...114,812,708
|
|
G |
Depdc1b |
DEP domain containing 1B |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of DEPDC1B mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 2:39,980,796...40,069,982
Ensembl chr 2:40,000,313...40,069,975
|
|
G |
Deptor |
DEP domain containing MTOR-interacting protein |
increases expression |
ISO |
sodium arsenate results in increased expression of DEPTOR mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 7:94,795,161...95,000,750
Ensembl chr 7:94,795,214...94,995,809
|
|
G |
Det1 |
DET1 partner of COP1 E3 ubiquitin ligase |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of DET1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 1:140,519,755...140,535,969
Ensembl chr 1:140,519,702...140,535,934
|
|
G |
Dhrs3 |
dehydrogenase/reductase 3 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of DHRS3 mRNA |
CTD |
PMID:12727804 |
|
NCBI chr 5:162,809,090...162,843,385
Ensembl chr 5:162,808,646...162,843,383
|
|
G |
Dhrs9 |
dehydrogenase/reductase 9 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of DHRS9 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 3:55,623,671...55,645,883
Ensembl chr 3:55,623,634...55,648,325
|
|
G |
Dhx32 |
DEAH-box helicase 32 (putative) |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of DHX32 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 1:205,789,442...205,848,727
Ensembl chr 1:205,789,442...205,842,428
|
|
G |
Diaph2 |
diaphanous-related formin 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of DIAPH2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr X:99,722,910...100,363,228
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
affects expression |
ISO |
sodium arsenate affects the expression of DIO1 mRNA |
CTD |
PMID:28813693 |
|
NCBI chr 5:126,894,837...126,911,532
Ensembl chr 5:126,895,286...126,911,520
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
affects expression multiple interactions |
ISO |
sodium arsenate affects the expression of DIO2 mRNA [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of DIO2 mRNA |
CTD |
PMID:28813693 PMID:32525701 |
|
NCBI chr 6:114,475,156...114,489,443
Ensembl chr 6:114,476,142...114,476,723
|
|
G |
Dipk1a |
divergent protein kinase domain 1A |
increases expression |
ISO |
sodium arsenate results in increased expression of DIPK1A mRNA |
CTD |
PMID:21795629 |
|
NCBI chr14:2,789,699...2,860,354
Ensembl chr14:2,789,650...2,860,333
|
|
G |
Dipk1b |
divergent protein kinase domain 1B |
decreases expression |
ISO |
sodium arsenate results in decreased expression of DIPK1B mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 3:4,083,797...4,091,550
Ensembl chr 3:4,083,864...4,092,289
|
|
G |
Dis3l2 |
DIS3-like 3'-5' exoribonuclease 2 |
decreases expression affects methylation |
ISO |
sodium arsenate results in decreased expression of DIS3L2 mRNA sodium arsenate affects the methylation of DIS3L2 promoter |
CTD |
PMID:20667999 |
|
NCBI chr 9:93,767,837...94,161,106
Ensembl chr 9:93,660,680...94,160,760
|
|
G |
Dll1 |
delta like canonical Notch ligand 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of DLL1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 1:57,318,621...57,326,732
Ensembl chr 1:57,318,708...57,327,379
|
|
G |
Dlx3 |
distal-less homeobox 3 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of DLX3 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr10:82,937,971...82,943,367
Ensembl chr10:82,937,971...82,943,348
|
|
G |
Dmd |
dystrophin |
increases expression |
ISO |
sodium arsenate results in increased expression of DMD mRNA |
CTD |
PMID:21795629 |
|
NCBI chr X:51,149,358...53,519,271
Ensembl chr X:51,286,737...53,519,259
|
|
G |
Dmkn |
dermokine |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of DMKN mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 1:89,215,266...89,229,696
Ensembl chr 1:89,215,266...89,229,696
|
|
G |
Dmpk |
DM1 protein kinase |
increases expression |
ISO |
sodium arsenate results in increased expression of DMPK mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 1:79,988,096...79,999,358
Ensembl chr 1:79,989,019...79,999,364
|
|
G |
Dmwd |
DM1 locus, WD repeat containing |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of DMWD mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 1:79,981,270...79,987,997
Ensembl chr 1:79,981,355...79,987,562
|
|
G |
Dmxl2 |
Dmx-like 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of DMXL2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 8:58,932,575...59,077,788
Ensembl chr 8:58,932,580...59,077,690
|
|
G |
Dnajb14 |
DnaJ heat shock protein family (Hsp40) member B14 |
decreases expression increases expression |
ISO |
sodium arsenate results in decreased expression of DNAJB14 mRNA sodium arsenate results in increased expression of DNAJB14 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 2:243,108,443...243,151,933
Ensembl chr 2:243,018,975...243,151,933
|
|
G |
Dnajb5 |
DnaJ heat shock protein family (Hsp40) member B5 |
decreases expression increases expression |
ISO |
sodium arsenate results in decreased expression of DNAJB5 mRNA sodium arsenate results in increased expression of DNAJB5 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 5:58,393,197...58,402,162
Ensembl chr 5:58,393,233...58,401,870
|
|
G |
Dnajc1 |
DnaJ heat shock protein family (Hsp40) member C1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of DNAJC1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr17:84,986,994...85,141,464
Ensembl chr17:84,986,991...85,141,210
|
|
G |
Dnajc19 |
DnaJ heat shock protein family (Hsp40) member C19 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of DNAJC19 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 2:120,503,093...120,531,782
Ensembl chr 2:120,504,130...120,531,782
|
|
G |
Dnajc3 |
DnaJ heat shock protein family (Hsp40) member C3 |
increases expression |
ISO |
sodium arsenate results in increased expression of DNAJC3 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr15:104,186,918...104,226,236
Ensembl chr15:104,186,792...104,226,329
|
|
G |
Dnase1l2 |
deoxyribonuclease 1 like 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of DNASE1L2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr10:13,812,335...13,814,514
Ensembl chr10:13,812,707...13,814,304
|
|
G |
Dock10 |
dedicator of cytokinesis 10 |
increases expression |
ISO |
sodium arsenate results in increased expression of DOCK10 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 9:86,424,638...86,571,854 NCBI chr 9:86,312,470...86,423,054
Ensembl chr 9:86,312,501...86,571,870
|
|
G |
Dock5 |
dedicator of cytokinesis 5 |
increases expression |
ISO |
sodium arsenate results in increased expression of DOCK5 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr15:44,449,108...44,627,774
Ensembl chr15:44,453,308...44,627,765
|
|
G |
Dock8 |
dedicator of cytokinesis 8 |
increases expression |
ISO |
sodium arsenate results in increased expression of DOCK8 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 1:242,934,685...243,153,472
Ensembl chr 1:242,959,488...243,153,465
|
|
G |
Dpp7 |
dipeptidylpeptidase 7 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of DPP7 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 3:2,569,135...2,573,387
Ensembl chr 3:2,569,135...2,573,387
|
|
G |
Dpp8 |
dipeptidylpeptidase 8 |
increases expression |
ISO |
sodium arsenate results in increased expression of DPP8 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 8:70,521,782...70,576,180
Ensembl chr 8:70,522,092...70,573,424
|
|
G |
Dpy19l4 |
dpy-19 like 4 |
increases expression |
ISO |
sodium arsenate results in increased expression of DPY19L4 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 5:24,503,074...24,560,077
Ensembl chr 5:24,504,614...24,560,063
|
|
G |
Dpysl3 |
dihydropyrimidinase-like 3 |
increases expression |
ISO |
sodium arsenate results in increased expression of DPYSL3 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr18:37,716,371...37,819,347
Ensembl chr18:37,716,143...37,819,097
|
|
G |
Dpysl4 |
dihydropyrimidinase-like 4 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of DPYSL4 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 1:211,423,022...211,438,533
Ensembl chr 1:211,423,022...211,438,531
|
|
G |
Dsc1 |
desmocollin 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of DSC1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr18:11,877,918...11,906,828
Ensembl chr18:11,877,561...11,906,827
|
|
G |
Dsc2 |
desmocollin 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of DSC2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr18:11,826,705...11,858,801
Ensembl chr18:11,826,706...11,858,754
|
|
G |
Dsg1 |
desmoglein 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of DSG1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr18:12,008,301...12,040,337
Ensembl chr18:12,008,759...12,038,053
|
|
G |
Dst |
dystonin |
decreases expression increases expression |
ISO |
sodium arsenate results in decreased expression of DST mRNA sodium arsenate results in increased expression of DST mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 9:37,902,336...38,296,961
Ensembl chr 9:37,902,303...38,196,273
|
|
G |
Dtna |
dystrobrevin, alpha |
increases expression |
ISO |
sodium arsenate results in increased expression of DTNA mRNA |
CTD |
PMID:21795629 |
|
NCBI chr18:14,544,725...14,671,514
Ensembl chr18:14,471,213...14,657,332
|
|
G |
Dtnbp1 |
dystrobrevin binding protein 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of DTNBP1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr17:20,090,136...20,182,332
Ensembl chr17:20,090,246...20,182,206
|
|
G |
Dtx3l |
deltex E3 ubiquitin ligase 3L |
increases expression |
ISO |
sodium arsenate results in increased expression of DTX3L mRNA |
CTD |
PMID:21795629 |
|
NCBI chr11:67,758,093...67,767,623 NCBI chr11:67,768,542...67,772,428
Ensembl chr11:67,757,928...67,767,622
|
|
G |
Dtx4 |
deltex E3 ubiquitin ligase 4 |
increases expression |
ISO |
sodium arsenate results in increased expression of DTX4 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 1:228,729,842...228,759,783
Ensembl chr 1:228,732,985...228,755,866
|
|
G |
Dus4l |
dihydrouridine synthase 4-like |
decreases expression |
ISO |
sodium arsenate results in decreased expression of DUS4L mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 6:50,925,987...50,943,546
Ensembl chr 6:50,928,397...50,943,488
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of DUSP1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr10:16,970,642...16,973,425
Ensembl chr10:16,970,626...16,973,418
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of DUSP10 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr13:104,284,660...104,321,455
Ensembl chr13:104,284,660...104,321,455
|
|
G |
Dusp16 |
dual specificity phosphatase 16 |
increases expression |
ISO |
sodium arsenate results in increased expression of DUSP16 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 4:168,470,141...168,551,346
Ensembl chr 4:168,472,412...168,517,177
|
|
G |
Dusp23 |
dual specificity phosphatase 23 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of DUSP23 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr13:91,018,670...91,019,862
Ensembl chr13:91,018,510...91,020,112
|
|
G |
Dvl1 |
dishevelled segment polarity protein 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of DVL1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 5:173,295,948...173,308,014
Ensembl chr 5:173,296,270...173,307,945
|
|
G |
Dync1h1 |
dynein cytoplasmic 1 heavy chain 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of DYNC1H1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 6:134,958,854...135,085,769
Ensembl chr 6:134,958,854...135,085,769
|
|
G |
Dynlrb2 |
dynein light chain roadblock-type 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of DYNLRB2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr19:49,016,919...49,028,400
Ensembl chr19:49,016,891...49,028,404
|
|
G |
Dynlt3 |
dynein light chain Tctex-type 3 |
increases expression |
ISO |
sodium arsenate results in increased expression of DYNLT3 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr X:14,633,342...14,642,356
Ensembl chr X:14,633,342...14,642,424
|
|
G |
Dyrk1a |
dual specificity tyrosine phosphorylation regulated kinase 1A |
increases expression |
ISO |
sodium arsenate results in increased expression of DYRK1A mRNA |
CTD |
PMID:21795629 |
|
NCBI chr11:34,858,339...34,958,733
Ensembl chr11:34,865,532...34,956,536
|
|
G |
Dysf |
dysferlin |
increases expression |
ISO |
sodium arsenate results in increased expression of DYSF mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 4:115,700,942...115,901,873
Ensembl chr 4:115,712,850...115,901,873
|
|
G |
Dzip1 |
DAZ interacting zinc finger protein 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of DZIP1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr15:104,117,551...104,168,574
Ensembl chr15:104,117,556...104,170,958
|
|
G |
Dzip3 |
DAZ interacting zinc finger protein 3 |
increases expression |
ISO |
sodium arsenate results in increased expression of DZIP3 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr11:54,404,777...54,475,361
Ensembl chr11:54,404,446...54,472,447
|
|
G |
E2f2 |
E2F transcription factor 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of E2F2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 5:154,516,611...154,540,228
Ensembl chr 5:154,522,119...154,540,265
|
|
G |
E2f3 |
E2F transcription factor 3 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of E2F3 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr17:36,334,136...36,408,831
Ensembl chr17:36,334,147...36,408,831
|
|
G |
Ece1 |
endothelin converting enzyme 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of ECE1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 5:156,215,469...156,318,652
Ensembl chr 5:156,215,417...156,318,671
|
|
G |
Eea1 |
early endosome antigen 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of EEA1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 7:37,101,415...37,186,534
Ensembl chr 7:37,018,459...37,186,732
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of EEF1A1 mRNA |
CTD |
PMID:12727804 |
|
NCBI chr 8:85,838,594...85,841,816
Ensembl chr 8:85,838,869...85,840,818
|
|
G |
Eef1a2 |
eukaryotic translation elongation factor 1 alpha 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of EEF1A2 mRNA |
CTD |
PMID:12727804 |
|
NCBI chr 3:176,657,104...176,666,282
Ensembl chr 3:176,657,107...176,666,282
|
|
G |
Efnb3 |
ephrin B3 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of EFNB3 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr10:56,161,431...56,168,819
Ensembl chr10:56,161,432...56,167,426
|
|
G |
Efs |
embryonal Fyn-associated substrate |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of EFS mRNA |
CTD |
PMID:32525701 |
|
NCBI chr15:33,579,952...33,590,217
Ensembl chr15:33,578,381...33,589,522
|
|
G |
Egfr |
epidermal growth factor receptor |
increases expression |
ISO |
sodium arsenate results in increased expression of EGFR mRNA |
CTD |
PMID:21795629 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Egr1 |
early growth response 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of EGR1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Egr2 |
early growth response 2 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of EGR2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr20:22,452,170...22,461,018
Ensembl chr20:22,454,463...22,459,025
|
|
G |
Egr3 |
early growth response 3 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of EGR3 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr15:51,756,683...51,762,080
Ensembl chr15:51,756,736...51,760,722
|
|
G |
Ehf |
ets homologous factor |
increases expression |
ISO |
sodium arsenate results in increased expression of EHF mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 3:93,176,257...93,216,484
Ensembl chr 3:93,178,163...93,216,495
|
|
G |
Eid1 |
EP300 interacting inhibitor of differentiation 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of EID1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 3:117,938,500...117,940,219
Ensembl chr 3:117,938,500...117,940,219
|
|
G |
Eif2s3 |
eukaryotic translation initiation factor 2 subunit gamma |
increases expression |
ISO |
sodium arsenate results in increased expression of EIF2S3X mRNA |
CTD |
PMID:21795629 |
|
NCBI chr X:63,268,106...63,291,125
Ensembl chr X:63,268,037...63,292,092
|
|
G |
Eif4e3 |
eukaryotic translation initiation factor 4E family member 3 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of EIF4E3 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 4:132,068,581...132,111,092
Ensembl chr 4:132,068,598...132,111,079
|
|
G |
Eif4ebp2 |
eukaryotic translation initiation factor 4E binding protein 2 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of EIF4EBP2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr20:31,055,292...31,072,469
Ensembl chr20:31,055,789...31,072,469
|
|
G |
Eif4h |
eukaryotic translation initiation factor 4H |
decreases expression |
ISO |
sodium arsenate results in decreased expression of EIF4H mRNA |
CTD |
PMID:30953684 |
|
NCBI chr12:25,093,119...25,109,805
Ensembl chr12:25,093,149...25,109,799
|
|
G |
Eif5 |
eukaryotic translation initiation factor 5 |
increases expression |
ISO |
sodium arsenate results in increased expression of EIF5 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 6:136,002,983...136,011,409
Ensembl chr 6:136,004,214...136,011,406
|
|
G |
Eif5a |
eukaryotic translation initiation factor 5A |
increases expression |
ISO |
sodium arsenate results in increased expression of EIF5A mRNA |
CTD |
PMID:30953684 |
|
NCBI chr10:56,527,075...56,531,615
Ensembl chr10:56,527,085...56,531,483
|
|
G |
Eif5a2 |
eukaryotic translation initiation factor 5A2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of EIF5A2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 2:115,336,646...115,354,203
Ensembl chr 2:115,337,439...115,354,203
|
|
G |
Eif5b |
eukaryotic translation initiation factor 5B |
increases expression |
ISO |
sodium arsenate results in increased expression of EIF5B mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 9:44,658,724...44,713,518
Ensembl chr 9:44,681,494...44,713,199
|
|
G |
Elf1 |
E74 like ETS transcription factor 1 |
decreases expression increases expression |
ISO |
sodium arsenate results in decreased expression of ELF1 mRNA sodium arsenate results in increased expression of ELF1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr15:61,772,544...61,868,442
Ensembl chr15:61,826,711...61,868,343
|
|
G |
Elmod1 |
ELMO domain containing 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ELMOD1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 8:58,486,078...58,542,884
Ensembl chr 8:58,486,078...58,542,844
|
|
G |
Elovl1 |
ELOVL fatty acid elongase 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ELOVL1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 5:137,255,868...137,260,486
Ensembl chr 5:137,255,908...137,260,483
|
|
G |
Elovl4 |
ELOVL fatty acid elongase 4 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ELOVL4 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 8:91,310,690...91,338,625
Ensembl chr 8:91,310,630...91,338,843
|
|
G |
Elp2 |
elongator acetyltransferase complex subunit 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of ELP2 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr18:16,544,515...16,581,086
Ensembl chr18:16,544,508...16,581,116
|
|
G |
Emilin1 |
elastin microfibril interfacer 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of EMILIN1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 6:26,821,249...26,829,013
Ensembl chr 6:26,821,255...26,828,972
|
|
G |
Emilin2 |
elastin microfibril interfacer 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of EMILIN2 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 9:119,594,049...119,653,675
Ensembl chr 9:119,594,629...119,653,255
|
|
G |
Eml2 |
EMAP like 2 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of EML2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 1:80,087,684...80,118,784
Ensembl chr 1:80,087,684...80,119,012
|
|
G |
Emp1 |
epithelial membrane protein 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of EMP1 mRNA |
CTD |
PMID:12727804 |
|
NCBI chr 4:169,161,076...169,181,967
Ensembl chr 4:169,147,243...169,181,966
|
|
G |
Enah |
ENAH, actin regulator |
increases expression |
ISO |
sodium arsenate results in increased expression of ENAH mRNA |
CTD |
PMID:21795629 |
|
NCBI chr13:100,297,421...100,415,335
Ensembl chr13:100,300,054...100,414,226
|
|
G |
Eno2 |
enolase 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ENO2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047 Ensembl chr 9:157,285,179...157,294,047
|
|
G |
Eno3 |
enolase 3 |
increases expression |
ISO |
sodium arsenate results in increased expression of ENO3 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr10:57,278,271...57,283,661
Ensembl chr10:57,278,307...57,283,653
|
|
G |
Ensa |
endosulfine alpha |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ENSA mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 2:197,752,544...197,759,882
Ensembl chr 2:197,752,544...197,759,882
|
|
G |
Eogt |
EGF domain specific O-linked N-acetylglucosamine transferase |
decreases expression |
ISO |
sodium arsenate results in decreased expression of EOGT mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 4:129,477,779...129,515,435
Ensembl chr 4:129,477,807...129,515,435
|
|
G |
Epb41 |
erythrocyte membrane protein band 4.1 |
increases expression |
ISO |
sodium arsenate results in increased expression of EPB41 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 5:150,081,727...150,243,186
Ensembl chr 5:150,084,611...150,167,077
|
|
G |
Epb41l1 |
erythrocyte membrane protein band 4.1-like 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of EPB41L1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 3:152,492,725...152,622,047
Ensembl chr 3:152,552,822...152,619,722 Ensembl chr 3:152,552,822...152,619,722
|
|
G |
Epb41l5 |
erythrocyte membrane protein band 4.1 like 5 |
increases expression |
ISO |
sodium arsenate results in increased expression of EPB41L5 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr13:35,622,472...35,673,449
Ensembl chr13:35,580,098...35,668,968
|
|
G |
Epcam |
epithelial cell adhesion molecule |
increases expression |
ISO |
sodium arsenate results in increased expression of EPCAM mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 6:11,282,194...11,308,870
Ensembl chr 6:11,281,964...11,298,216
|
|
G |
Epha1 |
Eph receptor A1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of EPHA1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 4:71,749,100...71,763,681
Ensembl chr 4:71,749,242...71,763,679
|
|
G |
Epha2 |
Eph receptor A2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of EPHA2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 5:159,845,773...159,874,203
Ensembl chr 5:159,845,774...159,874,206
|
|
G |
Epha4 |
Eph receptor A4 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of EPHA4 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 9:83,111,222...83,253,486
Ensembl chr 9:83,111,222...83,253,458
|
|
G |
Ephb6 |
Eph receptor B6 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of EPHB6 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 4:70,903,253...70,918,514
Ensembl chr 4:70,903,253...70,918,514
|
|
G |
Ephx3 |
epoxide hydrolase 3 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of EPHX3 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 7:14,212,470...14,217,778
Ensembl chr 7:14,212,470...14,217,778
|
|
G |
Epm2aip1 |
EPM2A interacting protein 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of EPM2AIP1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 8:119,524,039...119,531,387
Ensembl chr 8:119,524,039...119,531,387
|
|
G |
Epn2 |
epsin 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of EPN2 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr10:47,795,496...47,857,373
Ensembl chr10:47,795,524...47,857,326
|
|
G |
Eral1 |
Era-like 12S mitochondrial rRNA chaperone 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of ERAL1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr10:65,272,849...65,291,070
Ensembl chr10:65,272,849...65,291,064
|
|
G |
Erap1 |
endoplasmic reticulum aminopeptidase 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of ERAP1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 2:1,410,877...1,449,734
Ensembl chr 2:1,410,934...1,449,733
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ERBB2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ERBB3 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 7:2,989,202...3,010,610
Ensembl chr 7:2,989,340...3,010,350
|
|
G |
Erbin |
erbb2 interacting protein |
increases expression |
ISO |
sodium arsenate results in increased expression of ERBIN mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 2:33,880,860...33,952,806
Ensembl chr 2:33,881,024...33,920,837
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
increases expression |
ISO |
sodium arsenate results in increased expression of ERCC1 mRNA |
CTD |
PMID:11353140 |
|
NCBI chr 1:80,256,973...80,268,198
Ensembl chr 1:80,256,973...80,268,198
|
|
G |
Ereg |
epiregulin |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of EREG mRNA |
CTD |
PMID:32525701 |
|
NCBI chr14:18,577,620...18,591,395
Ensembl chr14:18,576,355...18,591,394
|
|
G |
Ergic2 |
ERGIC and golgi 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of ERGIC2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 4:182,569,086...182,600,258
Ensembl chr 4:182,569,089...182,600,258
|
|
G |
Erlec1 |
endoplasmic reticulum lectin 1 |
increases expression decreases expression |
ISO |
sodium arsenate results in increased expression of ERLEC1 mRNA sodium arsenate results in decreased expression of ERLEC1 mRNA |
CTD |
PMID:21795629 PMID:30953684 |
|
NCBI chr14:115,314,890...115,352,871
Ensembl chr14:115,314,890...115,352,562
|
|
G |
Ero1a |
endoplasmic reticulum oxidoreductase 1 alpha |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ERO1A mRNA |
CTD |
PMID:32525701 |
|
NCBI chr15:19,619,947...19,655,381
Ensembl chr15:19,619,973...19,655,381
|
|
G |
Esr1 |
estrogen receptor 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of ESR1 protein |
CTD |
PMID:10873715 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Esrp1 |
epithelial splicing regulatory protein 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of ESRP1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 5:24,576,988...24,631,758
Ensembl chr 5:24,576,991...24,631,698
|
|
G |
Etfb |
electron transfer flavoprotein subunit beta |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ETFB mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 1:98,472,776...98,486,940
Ensembl chr 1:98,472,745...98,486,976
|
|
G |
Etfdh |
electron transfer flavoprotein dehydrogenase |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of ETFDH mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 2:178,367,547...178,389,641
Ensembl chr 2:178,367,549...178,389,608
|
|
G |
Etfrf1 |
electron transfer flavoprotein regulatory factor 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of ETFRF1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 4:179,476,996...179,482,398
Ensembl chr 4:179,481,263...179,481,603
|
|
G |
Etl4 |
enhancer trap locus 4 |
increases expression |
ISO |
sodium arsenate results in increased expression of ETL4 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr17:87,173,265...87,681,268
Ensembl chr17:87,274,944...87,681,317
|
|
G |
Etnk1 |
ethanolamine kinase 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of ETNK1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 4:177,402,904...177,447,047
Ensembl chr 4:177,402,904...177,447,028
|
|
G |
Ets1 |
ETS proto-oncogene 1, transcription factor |
increases expression multiple interactions |
ISO |
sodium arsenate results in increased expression of ETS1 mRNA [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ETS1 mRNA |
CTD |
PMID:21795629 PMID:32525701 |
|
NCBI chr 8:33,756,634...33,879,625
Ensembl chr 8:33,816,386...33,879,625
|
|
G |
Evi5 |
ecotropic viral integration site 5 |
decreases expression increases expression |
ISO |
sodium arsenate results in decreased expression of EVI5 mRNA sodium arsenate results in increased expression of EVI5 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr14:2,892,738...3,038,237
Ensembl chr14:2,892,753...3,038,237
|
|
G |
Exoc5 |
exocyst complex component 5 |
decreases expression increases expression |
ISO |
sodium arsenate results in decreased expression of EXOC5 mRNA sodium arsenate results in increased expression of EXOC5 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr15:25,888,757...25,933,302
Ensembl chr15:25,887,070...25,933,268
|
|
G |
Extl3 |
exostosin-like glycosyltransferase 3 |
increases expression |
ISO |
sodium arsenate results in increased expression of EXTL3 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr15:48,420,419...48,465,171
Ensembl chr15:48,422,492...48,445,592
|
|
G |
F11r |
F11 receptor |
increases expression |
ISO |
sodium arsenate results in increased expression of F11R mRNA |
CTD |
PMID:30953684 |
|
NCBI chr13:89,826,272...89,850,151
Ensembl chr13:89,826,254...89,850,612
|
|
G |
F2r |
coagulation factor II (thrombin) receptor |
increases expression multiple interactions |
ISO |
sodium arsenate results in increased expression of F2R mRNA [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of F2R mRNA |
CTD |
PMID:21795629 PMID:32525701 |
|
NCBI chr 2:26,118,760...26,135,340
Ensembl chr 2:26,118,760...26,135,340
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
decreases expression multiple interactions |
ISO |
sodium arsenate results in decreased expression of FABP5 mRNA [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of FABP5 mRNA |
CTD |
PMID:12727804 PMID:32525701 |
|
NCBI chr 2:93,981,662...93,985,322
Ensembl chr 2:93,981,656...93,985,378
|
|
G |
Fads1 |
fatty acid desaturase 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of FADS1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 1:226,234,034...226,249,118
Ensembl chr 1:226,234,074...226,249,138
|
|
G |
Fam102b |
family with sequence similarity 102, member B |
decreases expression |
ISO |
sodium arsenate results in decreased expression of FAM102B mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 2:211,762,479...211,831,837
Ensembl chr 2:211,772,128...211,831,636
|
|
G |
Fam107a |
family with sequence similarity 107, member A |
increases expression |
ISO |
sodium arsenate results in increased expression of FAM107A mRNA |
CTD |
PMID:21795629 |
|
NCBI chr15:18,399,145...18,415,959
Ensembl chr15:18,399,515...18,415,965
|
|
G |
Fam126b |
family with sequence similarity 126, member B |
increases expression |
ISO |
sodium arsenate results in increased expression of FAM126B mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 9:65,406,136...65,478,399
Ensembl chr 9:65,406,138...65,442,257
|
|
G |
Fam168a |
family with sequence similarity 168, member A |
increases expression |
ISO |
sodium arsenate results in increased expression of FAM168A mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 1:165,723,278...165,880,612
Ensembl chr 1:165,724,451...165,878,652
|
|
G |
Fam171a2 |
family with sequence similarity 171, member A2 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of FAM171A2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr10:90,383,111...90,393,476
Ensembl chr10:90,383,813...90,393,317
|
|
G |
Fam174b |
family with sequence similarity 174, member B |
decreases expression |
ISO |
sodium arsenate results in decreased expression of FAM174B mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 1:135,081,596...135,180,266
Ensembl chr 1:135,083,974...135,162,685
|
|
G |
Fam184b |
family with sequence similarity 184, member B |
increases expression |
ISO |
sodium arsenate results in increased expression of FAM184B mRNA |
CTD |
PMID:21795629 |
|
NCBI chr14:69,970,034...70,086,018
Ensembl chr14:70,015,754...70,086,143
|
|
G |
Fam210a |
family with sequence similarity 210, member A |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of FAM210A mRNA |
CTD |
PMID:32525701 |
|
NCBI chr18:64,045,023...64,084,594
Ensembl chr18:64,045,432...64,084,556
|
|
G |
Fam25a |
family with sequence similarity 25, member A |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of FAM25A mRNA |
CTD |
PMID:32525701 |
|
NCBI chr16:10,702,264...10,706,073
Ensembl chr16:10,702,263...10,706,073
|
|
G |
Fam43a |
family with sequence similarity 43, member A |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of FAM43A mRNA |
CTD |
PMID:32525701 |
|
NCBI chr11:73,676,601...73,679,003
Ensembl chr11:73,676,601...73,678,984
|
|
G |
Fam83c |
family with sequence similarity 83, member C |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of FAM83C mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 3:151,365,623...151,371,568
Ensembl chr 3:151,365,811...151,371,501
|
|
G |
Fancg |
FA complementation group G |
increases expression |
ISO |
sodium arsenate results in increased expression of FANCG mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 5:58,448,060...58,456,416
Ensembl chr 5:58,448,822...58,455,819
|
|
G |
Far1 |
fatty acyl CoA reductase 1 |
decreases expression increases expression |
ISO |
sodium arsenate results in decreased expression of FAR1 mRNA sodium arsenate results in increased expression of FAR1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 1:178,351,674...178,412,838
Ensembl chr 1:178,351,680...178,431,395
|
|
G |
Farp2 |
FERM, ARH/RhoGEF and pleckstrin domain protein 2 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of FARP2 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 9:100,660,366...100,767,940
Ensembl chr 9:100,660,394...100,767,940
|
|
G |
Fastkd2 |
FAST kinase domains 2 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of FASTKD2 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 9:70,448,386...70,471,420
Ensembl chr 9:70,450,444...70,470,550
|
|
G |
Fat4 |
FAT atypical cadherin 4 |
increases expression |
ISO |
sodium arsenate results in increased expression of FAT4 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 2:125,751,818...125,879,398
Ensembl chr 2:125,752,130...125,879,387 Ensembl chr 2:125,752,130...125,879,387
|
|
G |
Fbln2 |
fibulin 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of FBLN2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 4:122,835,237...122,895,127
Ensembl chr 4:122,835,436...122,895,121
|
|
G |
Fbxl3 |
F-box and leucine-rich repeat protein 3 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of FBXL3 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr15:93,647,307...93,667,395
Ensembl chr15:93,647,310...93,667,395
|
|
G |
Fbxl7 |
F-box and leucine-rich repeat protein 7 |
increases expression |
ISO |
sodium arsenate results in increased expression of FBXL7 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 2:79,067,907...79,439,987
Ensembl chr 2:79,067,915...79,078,258
|
|
G |
Fbxo3 |
F-box protein 3 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of FBXO3 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 3:93,968,827...94,000,863
Ensembl chr 3:93,968,855...94,000,863
|
|
G |
Fbxo32 |
F-box protein 32 |
increases expression multiple interactions |
ISO |
sodium arsenate results in increased expression of FBXO32 mRNA [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of FBXO32 mRNA |
CTD |
PMID:21795629 PMID:32525701 |
|
NCBI chr 7:98,065,664...98,098,071
Ensembl chr 7:98,063,735...98,098,268
|
|
G |
Fbxo4 |
F-box protein 4 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of FBXO4 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 2:53,797,954...53,811,134
Ensembl chr 2:53,797,954...53,811,134
|
|
G |
Fbxw2 |
F-box and WD repeat domain containing 2 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of FBXW2 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 3:13,871,513...13,897,033
Ensembl chr 3:13,871,517...13,896,838
|
|
G |
Fcho2 |
FCH and mu domain containing endocytic adaptor 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of FCHO2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 2:28,927,918...29,029,271
Ensembl chr 2:28,926,107...29,029,176
|
|
G |
Fermt2 |
FERM domain containing kindlin 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of FERMT2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr15:19,807,806...19,876,557
Ensembl chr15:19,807,808...19,876,408
|
|
G |
Fetub |
fetuin B |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of FETUB mRNA |
CTD |
PMID:32525701 |
|
NCBI chr11:81,648,890...81,660,472
Ensembl chr11:81,648,885...81,660,395
|
|
G |
Fga |
fibrinogen alpha chain |
decreases expression |
ISO |
sodium arsenate results in decreased expression of FGA mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 2:181,997,562...182,013,726
Ensembl chr 2:182,006,242...182,013,763
|
|
G |
Fgd2 |
FYVE, RhoGEF and PH domain containing 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of FGD2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr20:6,973,356...6,990,026
Ensembl chr20:6,973,398...6,990,023
|
|
G |
Fgf14 |
fibroblast growth factor 14 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of FGF14 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr15:110,382,274...111,077,027
Ensembl chr15:110,385,217...110,612,681
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of FGFR1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr16:71,265,390...71,319,046
Ensembl chr16:71,266,248...71,319,449
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of FGFR3 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr14:82,272,322...82,287,739
Ensembl chr14:82,273,070...82,287,706
|
|
G |
Fggy |
FGGY carbohydrate kinase domain containing |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of FGGY mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 5:114,516,860...114,901,571
Ensembl chr 5:114,516,889...114,901,564
|
|
G |
Fgl2 |
fibrinogen-like 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of FGL2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 4:10,323,598...10,329,241
Ensembl chr 4:10,323,607...10,329,241
|
|
G |
Fhip1b |
FHF complex subunit HOOK interacting protein 1B |
decreases expression |
ISO |
sodium arsenate results in decreased expression of FAM160A2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 1:170,216,505...170,238,898
Ensembl chr 1:170,212,817...170,238,890
|
|
G |
Filip1 |
filamin A interacting protein 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of FILIP1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 8:87,257,312...87,453,432
Ensembl chr 8:87,256,264...87,419,564
|
|
G |
Filip1l |
filamin A interacting protein 1-like |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of FILIP1L mRNA |
CTD |
PMID:32525701 |
|
NCBI chr11:45,039,488...45,275,141
Ensembl chr11:45,039,461...45,124,423
|
|
G |
Fis1 |
fission, mitochondrial 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of FIS1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr12:22,750,485...22,765,324
Ensembl chr12:22,750,485...22,765,308
|
|
G |
Fitm2 |
fat storage-inducing transmembrane protein 2 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of FITM2 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 3:159,856,994...159,863,506
Ensembl chr 3:159,856,994...159,863,506
|
|
G |
Fkbp15 |
FKBP prolyl isomerase family member 15 |
increases expression |
ISO |
sodium arsenate results in increased expression of FKBP15 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 5:78,133,357...78,229,311
Ensembl chr 5:78,133,886...78,183,122
|
|
G |
Fktn |
fukutin |
increases expression |
ISO |
sodium arsenate results in increased expression of FKTN mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 5:70,522,001...70,578,270
Ensembl chr 5:70,528,688...70,578,273
|
|
G |
Flcn |
folliculin |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of FLCN mRNA |
CTD |
PMID:32525701 |
|
NCBI chr10:46,153,185...46,172,331
Ensembl chr10:46,153,188...46,172,309
|
|
G |
Flg |
filaggrin |
decreases expression multiple interactions |
ISO |
sodium arsenate results in decreased expression of FLG mRNA [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of FLG mRNA |
CTD |
PMID:11485391 PMID:12727804 PMID:32525701 |
|
NCBI chr 2:193,565,401...193,574,297
|
|
G |
Flg2 |
filaggrin family member 2 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of FLG2 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 2:193,480,880...193,485,463
Ensembl chr 2:193,483,793...193,485,313
|
|
G |
Flnb |
filamin B |
increases expression |
ISO |
sodium arsenate results in increased expression of FLNB mRNA |
CTD |
PMID:21795629 |
|
NCBI chr15:18,750,152...18,883,019
Ensembl chr15:18,750,118...18,883,005
|
|
G |
Flot2 |
flotillin 2 |
decreases expression increases expression |
ISO |
sodium arsenate results in decreased expression of FLOT2 mRNA sodium arsenate results in increased expression of FLOT2 mRNA |
CTD |
PMID:21795629 PMID:30953684 |
|
NCBI chr10:65,304,901...65,329,332
Ensembl chr10:65,304,902...65,329,312
|
|
G |
Flt4 |
Fms related receptor tyrosine kinase 4 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of FLT4 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr10:35,078,782...35,120,296
Ensembl chr10:35,078,726...35,121,599
|
|
G |
Flvcr1 |
FLVCR heme transporter 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of FLVCR1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr13:109,578,294...109,624,235
Ensembl chr13:109,578,074...109,629,482
|
|
G |
Fmnl2 |
formin-like 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of FMNL2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 3:38,400,409...38,677,637
Ensembl chr 3:38,559,914...38,675,878
|
|
G |
Fmo2 |
flavin containing dimethylaniline monoxygenase 2 |
increases expression multiple interactions |
ISO |
sodium arsenate results in increased expression of FMO2 mRNA [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of FMO2 mRNA |
CTD |
PMID:21795629 PMID:32525701 |
|
NCBI chr13:80,752,526...80,775,264
Ensembl chr13:80,755,058...80,775,264
|
|
G |
Fmo5 |
flavin containing dimethylaniline monoxygenase 5 |
increases expression |
ISO |
sodium arsenate results in increased expression of FMO5 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 2:199,796,870...199,823,927
Ensembl chr 2:199,796,881...199,823,927
|
|
G |
Fn1 |
fibronectin 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of FN1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
|
|
G |
Fnbp1 |
formin binding protein 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of FNBP1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 3:9,865,657...9,936,333
Ensembl chr 3:9,861,237...9,936,405
|
|
G |
Fnbp4 |
formin binding protein 4 |
increases expression |
ISO |
sodium arsenate results in increased expression of FNBP4 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 3:79,570,610...79,610,122
Ensembl chr 3:79,570,625...79,610,454
|
|
G |
Fnip1 |
folliculin interacting protein 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of FNIP1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr10:39,786,687...39,870,188
|
|
G |
Folr2 |
folate receptor beta |
multiple interactions increases response to substance |
ISO |
Folic Acid affects the reaction [FOLR2 gene mutant form results in increased susceptibility to sodium arsenate] |
CTD |
PMID:11749123 PMID:16620997 |
|
NCBI chr 1:166,915,045...166,933,377
Ensembl chr 1:166,915,045...166,919,302
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression increases expression |
ISO |
sodium arsenate results in decreased expression of FOS mRNA sodium arsenate results in increased expression of FOS mRNA |
CTD |
PMID:11353140 PMID:21795629 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
sodium arsenate results in increased expression of FOSB mRNA |
CTD |
PMID:11353140 |
|
NCBI chr 1:80,214,691...80,221,417
Ensembl chr 1:80,214,494...80,221,710
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO |
sodium arsenate results in increased expression of FOSL1 mRNA [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of FOSL1 mRNA |
CTD |
PMID:11353140 PMID:32525701 |
|
NCBI chr 1:220,826,560...220,835,066
Ensembl chr 1:220,826,560...220,835,066
|
|
G |
Foxa1 |
forkhead box A1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of FOXA1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 6:78,516,579...78,549,669
Ensembl chr 6:78,545,804...78,549,669
|
|
G |
Foxc1 |
forkhead box C1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of FOXC1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr17:33,947,501...33,951,484
Ensembl chr17:33,947,506...33,951,484
|
|
G |
Foxd1 |
forkhead box D1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of FOXD1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 2:28,460,068...28,462,488
Ensembl chr 2:28,460,068...28,462,488
|
|
G |
Foxf1 |
forkhead box F1 |
increases expression |
ISO |
sodium arsenate results in increased expression of FOXF1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr19:53,012,306...53,016,100
Ensembl chr19:53,012,332...53,016,086
|
|
G |
Foxp1 |
forkhead box P1 |
increases expression |
ISO |
sodium arsenate results in increased expression of FOXP1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 4:131,362,178...131,963,466
Ensembl chr 4:131,366,744...131,694,755
|
|
G |
Foxred1 |
FAD-dependent oxidoreductase domain containing 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of FOXRED1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 8:36,401,317...36,410,589
Ensembl chr 8:36,403,493...36,410,612
|
|
G |
Frem2 |
FRAS1 related extracellular matrix 2 |
increases expression |
ISO |
sodium arsenate results in increased expression of FREM2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 2:142,747,501...142,885,604
Ensembl chr 2:142,747,501...142,885,604
|
|
G |
Frmd4b |
FERM domain containing 4B |
decreases expression |
ISO |
sodium arsenate results in decreased expression of FRMD4B mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 4:129,658,137...129,984,735
Ensembl chr 4:129,658,840...129,846,642
|
|
G |
Frmpd1 |
FERM and PDZ domain containing 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of FRMPD1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr 5:60,735,413...60,837,773
Ensembl chr 5:60,809,762...60,837,764
|
|
G |
Fryl |
FRY like transcription coactivator |
increases expression |
ISO |
sodium arsenate results in increased expression of FRYL mRNA |
CTD |
PMID:21795629 |
|
NCBI chr14:37,551,109...37,757,511
Ensembl chr14:37,551,940...37,756,149
|
|
G |
Fth1 |
ferritin heavy chain 1 |
increases expression multiple interactions |
ISO |
sodium arsenate results in increased expression of FTH1 mRNA [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of FTH1 mRNA |
CTD |
PMID:12727804 PMID:32525701 |
|
NCBI chr 1:226,030,940...226,033,228
Ensembl chr 1:226,030,938...226,033,228
|
|
G |
Ftl1 |
ferritin light chain 1 |
increases expression multiple interactions |
ISO |
sodium arsenate results in increased expression of FTL mRNA [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of FTL mRNA |
CTD |
PMID:12727804 PMID:32525701 |
|
NCBI chr 1:101,448,190...101,450,034
Ensembl chr 1:101,448,346...101,449,829
|
|
G |
Fto |
FTO, alpha-ketoglutarate dependent dioxygenase |
increases expression |
ISO |
sodium arsenate results in increased expression of FTO mRNA |
CTD |
PMID:21795629 |
|
NCBI chr19:16,774,549...17,115,098
Ensembl chr19:16,772,744...17,115,113
|
|
G |
Fubp1 |
far upstream element binding protein 1 |
increases expression |
ISO |
sodium arsenate results in increased expression of FUBP1 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 2:257,425,676...257,452,745
Ensembl chr 2:257,425,679...257,449,568
|
|
G |
Fus |
FUS RNA binding protein |
increases expression |
ISO |
sodium arsenate results in increased expression of FUS mRNA |
CTD |
PMID:21795629 |
|
NCBI chr 1:199,412,805...199,426,705
Ensembl chr 1:199,412,834...199,426,702
|
|
G |
Fxr1 |
FMR1 autosomal homolog 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of FXR1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 2:120,529,716...120,570,356
Ensembl chr 2:120,512,899...120,570,355
|
|
G |
Fzd2 |
frizzled class receptor 2 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of FZD2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr10:90,550,147...90,552,057
Ensembl chr10:90,550,147...90,552,057
|
|
G |
G0s2 |
G0/G1switch 2 |
decreases expression multiple interactions |
ISO |
sodium arsenate results in decreased expression of G0S2 mRNA [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of G0S2 mRNA |
CTD |
PMID:21795629 PMID:32525701 |
|
NCBI chr13:112,004,140...112,005,052
Ensembl chr13:112,004,140...112,005,052
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in increased expression of G6PD mRNA |
CTD |
PMID:32525701 |
|
NCBI chr X:156,274,800...156,293,935
Ensembl chr X:156,274,800...156,293,926
|
|
G |
Gabra6 |
gamma-aminobutyric acid type A receptor subunit alpha6 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of GABRA6 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr10:27,847,447...27,862,896
Ensembl chr10:27,847,439...27,862,868
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
ISO |
sodium arsenate analog results in increased expression of GADD45A mRNA; sodium arsenate results in increased expression of GADD45A mRNA |
CTD |
PMID:11353140 PMID:23221991 |
|
NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
decreases expression increases expression |
ISO |
sodium arsenate results in decreased expression of GADD45G mRNA sodium arsenate results in increased expression of GADD45G mRNA |
CTD |
PMID:21795629 |
|
NCBI chr17:13,391,474...13,393,219
Ensembl chr17:13,391,467...13,393,243
|
|
G |
Galnt7 |
polypeptide N-acetylgalactosaminyltransferase 7 |
increases expression |
ISO |
sodium arsenate results in increased expression of GALNT7 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr16:35,935,059...36,062,734
Ensembl chr16:35,934,970...36,062,719
|
|
G |
Galr2 |
galanin receptor 2 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of GALR2 mRNA |
CTD |
PMID:21795629 |
|
NCBI chr10:105,156,793...105,159,221
Ensembl chr10:105,156,632...105,237,611
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
EXP |
[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog]; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog] |
CTD |
PMID:15788719 |
|
NCBI chr 4:157,676,336...157,680,322
Ensembl chr 4:157,676,595...157,679,962
|
|
G |
Gapvd1 |
GTPase activating protein and VPS9 domains 1 |
decreases expression |
ISO |
sodium arsenate results in decreased expression of GAPVD1 mRNA |
CTD |
PMID:30953684 |
|
NCBI chr 3:13,751,572...13,825,573
Ensembl chr 3:13,753,165...13,824,870
|
|
G |
Gas1 |
growth arrest-specific 1 |
multiple interactions |
ISO |
[sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of GAS1 mRNA |
CTD |
PMID:32525701 |
|
NCBI chr17:4,846,116...4,849,350
Ensembl chr17:4,846,789...4,847,940
|
|
G |
Gas2l3 |
growth arrest-specific 2 like 3 |
decreases expression increases expression |
ISO |
sodium arsenate results in decreased expression of GAS2L3 mRNA sodium arsenate results in increased expression of GAS2L3 mRNA |
CTD |
|